

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Applicant(s) : Catherine M. Verfaillie et al.
Application No. : 10/561,826
Filed : October 17, 2006
Title : Neuronal Differentiation of Stem Cells
Examiner : Chang Yu Wang
Art Unit : 1649
Attorney Docket : 890003-2006.1

DECLARATION UNDER 37 C.F.R. § 1.132

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned, Catherine M. Verfaillie, Ph.D., declares and states:

I am Professor of Medicine and Director Stem cell Institute, KULeuven, Leuven. I am a co-inventor on the above-captioned patent application.

I am the subject of the attached *Curriculum Vitae* and author of the publications listed on the attachment to the *Curriculum Vitae*. On the information and facts contained in those documents, I submit that I am an expert in the field of Stem cell research. In view of these credentials, I believe that I am qualified to speak on the skill and knowledge of the person of ordinary skill in these fields.

I have read and understand the subject matter of the above-captioned patent application. I have read the first Office Action, dated March 17, 2008, and the second Office Action, dated December 24, 2008. I have read and understand the references cited by the Examiner to support the rejections in the Office Actions. These include U.S. 2003/0211605 to Lee et al. ("Lee") and WO 02/086073 to Studer et al. ("Studer").

It is my opinion, based on the scientific evidence and reasoning below, that the rejections are based on an incorrect assumption about (1) how cells should respond to basic fibroblast growth factor (bFGF), fibroblast growth factor 8 (FGF8), Sonic Hedgehog (SHH), and brain-derived neurotrophic factor (BDNF) when these are administered simultaneously as opposed to when these are administered sequentially, and (2) the cell type being acted upon by bFGF, FGF8, SHH, and BDNF in the cited art as opposed to the claimed method.

In the earlier Office Action, on page 6, the Examiner rejects the claims as being obvious over Studer in view of Lee. In the later Office Action, the Examiner provides particular reasons for this rejection. Specifically, the Examiner appears to believe that one would generally expect the same result whether one adds all factors simultaneously or sequentially. Specifically, the Examiner states on page 7 of the Office Action, "...at the end of the final steps, the culture medium contains the identical growth factors as those in Studer's to induce neuronal differentiation." The Examiner then reasons, "...because at the end the culture medium still contains the same growth factors and the same cultured ES cells, ...would be induced to differentiate into neurons." (Emphasis added.) Essentially, the Examiner appears to take the position that sequential exposure should have no significant effect because the factors and the cells exposed to them are the same. I do not agree with this reasoning for the reasons that follow.

The End Product of Sequential Exposure to Factors Cannot be Reasonably Predicted Based on the Results of Simultaneous Exposure to the Same Factors

When one introduces a cocktail of factors, as Studer and Lee have done, all the factors are exposed at once to one discrete cell type as to functional, transcriptional, translational, and morphological characteristics. Thus, the factors are acting at the same time on the same cell. Such exposure produces a certain end product. But, in the claimed methods, there are three phenotypically discrete cell types that are being acted upon: (1) the starting cells, (2) the cells that have been exposed to bFGF but not to FGF8 and SHH, and (3) the cells that have been exposed to bFGF, FGF8 and SHH, but not BDNF. Each mitogen would have a specific effect on the cell to produce a phenotypically discrete cell type. So, if one

exposes a cell to bFGF, FGF8, SHH, and BDNF at the same time, the FGF8/SHH is not acting on a cell with a phenotype created by exposure only to bFGF; and the BDNF is not acting on a cell with a phenotype created by exposure only to bFGF, SHH, and FGF8. Therefore, contrary to what the Examiner asserts, when all the factors are in the medium, they are not acting on the "same cultured ES cells." Because of this, one cannot reasonably predict that the result will be the same as the result obtained by Studer and/or Lee.

Although we have not done an experimental comparison between the Studer and Lee end products and the end products obtained using our own steps a) through c), I will discuss an application of the principle illustrated with a differentiation protocol that we conducted in our laboratory pertaining to differentiation of adult bone marrow stem cells into functional hepatocyte-like cells (Snykers et al., *Toxicological Sciences*, 94:330-341 (2006)). Although the reference is directed to differentiation of stem cells into hepatocytes, the principle applies: sequential exposure to factors can result in quite a different end product than simultaneous exposure ("cocktail").

As reported in this reference, we compared the end product obtained by using a cocktail of factors versus sequential exposure to the factors. I will not go into great detail about this reference as the Examiner is fully qualified to assess the reference. However, I will briefly give an outline of the rationale and the results. It had been previously been shown that bone marrow stem cells could differentiate into hepatocyte-like cells from a simultaneous exposure to a mixture of cytokines and growth factors. To try to improve the end product, the cells were exposed to the same factors in a sequential way. Characterization of the cells over a period of time and after exposure to each factor were characterized in several ways: (1) morphology; (2) mRNA expression of hepatocyte-specific genes; (3) protein expression of hepatocyte-specific genes; and (4) hepatic functionality as assessed by albumin secretion, ureogenesis, glycogen storage, and CYP protein expression activity and inducibility.

Our results showed the following. With respect to morphology, using the sequential procedure, the stem cells acquired morphological features similar to those of primary hepatocytes, particularly polygonal-

shaped and bi-nucleated cells. In contrast, using the previous approach, a heterogeneous population of epithelioid cells and other cell types was obtained with no polygonal-shaped cells and only a few bi-nucleated cells. With respect to liver associated genes and proteins, more than 85% of these epithelioid cells expressed these genes and expressed them in a comparable time-dependent manner as observed during *in vivo* liver embryogenesis. In contrast, with the cells exposed to the cocktail, the expression patterns differed from the normal sequence in that HNF1 α expression preceded that of albumin. In addition, significantly lower levels of liver-specific markers were expressed. With respect to functional maturation, this occurred with both experimental protocols but to a different extent. Hepatic metabolic functions, including albumin secretion, urea production, etc., were manifested most prominently upon sequential exposure to hepatogenic factors.

This illustrates the principle that the end product of sequential exposure to factors cannot be reasonably predicted based on the results of simultaneous exposure to the same factors.

My understanding is that the rejection of obviousness must be based on motivation to change the Studer/Lee procedure. It is my opinion that one would not have been motivated to alter the procedure of Studer and/or Lee because they would not have reasonably expected to produce the same result. Further, my understanding is that the rejection of obviousness must include a reasonable expectation that the same end product would be obtained. As I understand it, another way of looking at this is that it must be reasonably predictable that the same end product would be produced by simultaneous and sequential exposure to the factors. The Examiner seems to assert that position. But, it is my opinion as an expert in the field, that it was not reasonably predictable that the end product in the prior art would be produced by sequential exposure to the factors.

Summary

In the Studer and Lee method, one discrete cell type (neuronal commitment) is exposed to all three factors at once to create a discrete, functional, morphological, and transcriptional and translational profile. Using

the sequential method, however, the starting cells are first exposed to bFGF, which creates a cell with a specific morphology, function, and transcriptional and translational profile. It is this cell that is acted upon by SHH and FGF8, not the original starting cell as in the "cocktail" method. Then, exposure to FGF8 and SHH produces a cell with a second discrete type of morphology, function, and transcription and translational profile. It is this cell that is acted on by the BDNF, not the original starting cell as in the "cocktail" method. That is what makes the end product not reasonably predictable.

Studer/Lee Do Not Apply the Factors to Multipotent Cells

I also point out that Studer/Lee do not apply bFGF to embryonic stem cells, i.e., to a multipotent stem cell. Studer/Lee apply bFGF to a cell already committed to a neural fate. Studer/Lee form embryoid bodies from embryonic stem cells and grow these embryoid bodies without any differentiation factors, selecting for the cells that have undergone neural commitment. It is those cells that have undergone neural commitment that are exposed to the mitogen(s), SHH, and FGF8. The person of ordinary skill would have expected that neural commitment was needed prior to the application of mitogen(s) SHH and FGF8.

In contrast, in the claimed methods, bFGF is applied directly to multipotent stem cells and not to a neurally committed cell. In fact, it is the bFGF that induces neural commitment in these cells.

For this reason alone, I believe that the claimed method would not motivate one to practice the claimed method.

CONCLUSION

It is my opinion, based on the scientific evidence and reasoning set forth above, that the rejection lacks sufficient scientific basis for finding obviousness.


In my opinion, the person of ordinary skill in this field would not have been motivated to drastically change the approach of Studer and/or Lee from a cocktail approach to a sequential approach and would

not have had a reasonable expectation that the same results would be obtained if they did change the approach.

The Studer/Lee method applied to a neural committed cell, not an embryonic stem cell; therefore, the person of ordinary skill could not have reasonably expected successful application of the Studer/Lee method (i.e., exposure to mitogen(s) FGF8 and SHH) unless embryonic stem cells were committed to a neural fate before the factors were applied.

All statements made herein of my own knowledge are true and all statements made on information believed to be true. These statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

6/1/09
Date
11459190.1


Catherine M. Verfaillie, Ph.D.

Curriculum vitae: Catherine Maria Verfaillie
Januari, 2009

ADDRESS: Interdepartementaal Stamcel Instituut
Katholieke Universiteit Leuven
UZ Gasthuisberg
Herestraat 49
3000 Leuven
Belgium
Tel : +32 16 33 02 95
Fax : +32 16 33 02 94
E-mail: catherine.verfaillie@med.kuleuven.be

CITIZENSHIP: Belgium
Permanent Resident USA

EDUCATION: M.D.: U. of Leuven Medical School, Leuven, Belgium, 1975-1982

POST-GRADUATE TRAINING:

Internship: 1982-83, AZ St Jan Hospital, Brugge, Belgium
Residency: 1983-85, U. of Leuven, Belgium
Fellow in Hematology: 1985-87, U. of Leuven, Belgium
Post-doctoral Fellow: 1987-89, U. of Minnesota, Minneapolis, MN

PROFESSIONAL APPOINTMENTS:

Instructor, Dep. of Medicine, University of Minnesota, 1989-90,
Assistant Professor of Medicine, University of Minnesota 1991-1995
Associate Professor of Medicine, University of Minnesota 1995-1998
Professor of Medicine, University of Minnesota 1998-
Director Stem Cell Biology Program, University of Minnesota, 1996-1999
Director, Stem Cell Institute, University of Minnesota, 1999-2006
Buitengewoon Hoogleraar, Katholieke Universiteit, Leuven, 2005-
Director, Stamcel Instituut, Katholieke Universiteit, Leuven, 2005-

Member, BME Graduate Program, since 1992
Member, MICA Graduate Program, since 1992
Member, MD/Ph.D Graduate Program, since 1994
Member Cancer Center, 1994
Member, GCD Graduate Program, since 2000
Member, Clinical Laboratory Science Graduate Program, since 2000
Member, Neuroscience Graduate Program, since 2002
Member Doctoral School, Department of molecular and Cellular Therapy, K.U.Leuven

CERTIFICATION:

FMGEMS-1987
FLEX-1990

HONORS:

M.D., Summa Cum Laude, 1982
Special Fellow, Leukemia Society of America, 1991
Special Fellow, 'Fundacion Internacional Jose Carreras Para La Lucha Contra La Leucemia ', 1991
Young Investigator Award, International Society of Exp. Hematology, 1992
Scholar, Leukemia Society of America, 1995
Outstanding Investigator Award, Central Society, 1996
Elected, Member, American Society of Clinical Investigation, 1996
Tulloch Chair in Stem Cell Biology, Genetics and Genomics, 1999
Anderson Chair in Stem Cell Biology, 1999
Elected, Councilor, American Society of Clinical Investigation, 2001
McKnight's Presidential Chair in Stem Cell Biology, 2001
Elected, Member, American Association of Professors, 2003

Vice President, International Society of Experimental Hematology, 2002

President Elect, International Society of Experimental Hematology, 2002

President, International Society of Experimental Hematology, 2004

4th Annual Landazuri Award, University of Navarra, Pamplona, Spain 2002

Damashek Medal, American Society of Hematology, 2002

Honorary Doctorate, Katholieke Universiteit, Belgium, 2003

Distinguished Woman Scholar Award, University Of Minnesota, 2003

2003 Jose Carreras Award, European Society of Hematology, 2003

Forum Engelberg Prize, Lucerne, Switzerland, 2003

Gulden Spoor voor Vlaamse Internationale Uitstraling, Vlaanderen-Europa, 2003

Star Award, Minnesota Hematology Oncology, 2004

Stewart-Niewiarowski Award for Women in Vascular Biology, 2004

Jimenez Diaz Price for Scientific Achievements in Research, 2004

Vlerick Award, 2005

Honorary Member, BeWiSe, 2005

Gabriella Moortgat Prijs, 2006

Bijzonder Hoogleraar, TEFAF Oncology Wisselleerstoel, 2009, Faculty of Health, Medicine, and Life Sciences, Universiteit van Maastricht

Cariplo Professor, University of Pavia, Italy, 2009-2011

NAMED LECTURES:

Presidential Symposium, American Society of Hematology, San Francisco, 2000

Nobel-Forum Lecture series, Karolinska Institute, Stockholm, Sweden, 2000

Linda Laubenstein Memorial Lecture, NYU, New York, 2000

Clement Finch Visiting Professor, University of Washington, Seattle, 2002

4th Annual Landazuri Lecture, University of Navarra, Pamplona, Spain, 2002

Gerhard Smith Memorial Lectureship, City of Hope, CA, 2002

Fiftieth Chalmers J Lyons Memorial Lectureship, AAOMS, Chicago, IL, 2002

Forum Engelberg Award Seminar, Lucerne, Switzerland, 2003

Hohenberg Lecture, university of Pennsylvania, PA, 2003

Kilo Professorship, Washington University, St. Louis, MO, 2003

Evans Lecture, Boston University, Boston, MA, 2003

Stewart-Niewiarowski lecture, Temple University, Boston, MA, 2004

KeKule Lecture 2004, Antwerp, Belgium, 2004

NIH Director's Lecture, Washington, DC, 2004

Bendit Lecture, University of Washington, Seattle, WA, 2004

Jimenez Diaz Commemorative Lecture, Madrid, Spain, 2004

Presidential Symposium, ASGT, Minneapolis, MN, 2004

Latta Lecture, University of Nebraska, Omaha, 2005

Presidential Symposium, Am Soc for Investigative Pathology, San Diego, 2005

Moloney Lecture, Brigham & Women's Hospital, Boston MA, 2005

Ada Comstock Inaugural Lecture, Minneapolis, MN, 2005

Brecher Lecture, San Francisco, CA, 2005

Visiting Professor Department of Medicine, Vanderbilt University, 2006

Presidential Symposium, ESTRO, Leipzig, Germany, 2006

Pierre Strickmans Memorial Lecture, Brussels 2007

PROFESSIONAL ASSOCIATIONS:

American Federation for Clinical Research (AFCR)

American Society of Gene Therapy (ASGT)

American Society of Hematology (ASH)

American Society of Stem Cell and Bone Marrow Transplantation (ASBMT)

International Society for Hematotherapy and Graft Engineering (ISHAGE)

International Society of Experimental Hematology (ISEH)

International Bone Marrow Transplantation Registry (IBMTR)

Autologous Bone Marrow Transplantation Registry (ABMTR)

International Society for Stem Cell Research (ISSCR)

COMMITTEE ASSIGNMENTS (Extramural):

Treasurer, International Society of Experimental Hematology, 1997-2001

Councilor, American Society of Clinical Investigation, 2001-2005

Board of Directors, American Society of Blood and Bone Marrow Transplantation, 2001-2005

Councilor, Society Cell transplantation, 2002-2006
 Member, Scientific Committee of the European School of Hematology, 2004-
 Chair, Policy Committee, ISSCR, 2002-2006
 Member, Scientific Subcommittee on Transfusion Medicine, ASH, 1996-1998
 Member, Scientific Subcommittee on Growth Factors, ASH, 1998-2002
 Member, Awards Committee, ASH, 2003-2007
 Member, Publications Committee, ISEH, 2001-2005
 Member, Committee on Hemopoietic Cell and Gene Therapy, ASGT, 98-02
 Member, Stem Cell Evaluation Committee, ISHAGE, 1997-2001
 Member, Mesenchymal Stem Cell Committee, ISHAGE, 1999-2004
 Member, Stem cell Expansion Committee, ISHAGE, 2001-2003

Chair, VA Merit Award Heme Study Section, 2001-2002
 Member, NIH study section, Heme I, 2000-2004
 Member, VA Merit Award Heme Study Section, 1999-2002
 Member, LSA Translational Awards Review Committee, 1999-2004
 Member, Telethon Scientific Committee, Italy, 2001-2005
 CIRM review committee, 2006-
 Review committee, Connecticut Stem Cell Initiative, 2006-
 Member CNRS review panel, Belgium, 2008-2012

Ad hoc reviewer, Juvenile Diabetes Research Fund
 Ad hoc reviewer, Muscular Dystrophy Association
 Ad hoc reviewer, Leukemia Research Fund, Great Britain
 Ad hoc reviewer, Wellcome Trust, Great Britain
 Ad hoc reviewer, Research Council, Canada
 Ad hoc reviewer, Nationaal Fonds Wetenschappelijk Onderzoek, Belgium
 Ad hoc reviewer, Associazione Italiana per la Ricerca Sul Cancro
 Ad hoc reviewer, Israel Science Foundation
 Ad hoc reviewer, Dutch Cancer Society
 Ad Hoc reviewer, Medical and Health Services Research Division, Ireland.
 Ad hoc reviewer, European Commission, FP6
 Ad hoc reviewer, European Commission, FP7
 Ad hoc reviewer, European Research Council, 2007-

COMMITTEE ASSIGNMENTS (Intramural):

Promotion and Tenure Committee, Department of Medicine 1997-2001
 Research Committee, Department of Medicine, since 1997
 Steering Committee MD/Ph.D. Program, 1998-2005
 Molecular Medicine Planning Committee, 1998-2000
 AHC, Functional Genomics Advisory Group, 2000-2004
 Consortium on Law and Values in Health, Environment & the Life Sciences, 2001-6

CONSULTANT/ADVISOR

Member International Scientific Advisory Board, UK Government and Wellcome Trust Joint Infrastructure Fund, 1999
 Member Advisory Committee, Institute of Hematology, Chinese Academy of Sciences & Peking Union Medical College, 2000-2005
 Member, Advisory Committee Tissues of Life Project, Science Museum of Minnesota, 2000-2006
 Member Scientific Advisory Panel, University of Nebraska Stem Cell Biology Research Center, 1999-2004
 Member Scientific Advisory Panel for National Stem Cell Resource, Coriell Institute, Camden, NJ, 2000-2004
 Member, Advisory Committee, Mayo Clinic Myeloma PO1, 1998-2004
 Member, Stem Cell Advisory Committee, National Research Institute, Taiwan, 2002-
 Consultant, Athersys Inc., Cleveland, OH, 2002-
 Member, Advisory Board, Center for Transgene Therapy and Gene Therapy, VIB, Leuven, Belgium, 2003
 Member Advisory Panel, Stem Cell GAP, NIH, 2003-5
 Member, Scientific Advisory Board, Oncostem Therapeutics, Salamanca, Spain, 2004-2007
 Member, Scientific Advisory Board, Toronto McLaughlin Centre, 2004-2007
 Member, Scientific Advisory Board, Framework 6 Program Beta Cells, 2004
 Member, Scientific Advisory Board, DPTE, 2005-
 Member, Scientific Advisory Board, Case Western University Stem Cell Institute, 2005-2008
 Lid Raad van Advies, EOS, 2005-

Member Advisory Committee, Itinera, 2006-
 Advisory Board Regenerative Medicine, the Netherlands, 2007-2009
 Co-Chair Research and Quality Assurance Evaluation, Lund University, 2008
 Member, Review Committee Science Foundation Ireland REMEDI CSET, 2008
 Member, Scientific Advisory Committee, Fondazione Roma, 2008-
 Member, Advisory Board, FP7 Infarct Cell Therapy project, PI E Hofer, 2008-
 Member International Advisory Board Norway Stem Cell Center, 2008-
 Member Advisory Board, EC project "Infarct Cell Therapy", 2009-

ASSOCIATE EDITOR:

Experimental Hematology, 2003-2008
 Experimental Hematology, 1998-200
 Leukemia, 1997-2002
 Hematologia, Citocinas, Immunoterapia Y Terapia Cellular, 1997-2002
 Stem Cell Reviews, 2004-2008
 PloS-1, 2008-

EDITORIAL BOARD:

Blood, 1995-1999
 Experimental Hematology, 1996-1998
 Leukemia, 1996-1997
 Cytotherapy, 1999-2003
 Journal of Biology of Blood and Marrow Transplantation, 2001-2005
 Cloning & Stem Cells, 2001-2005
 Current Gene Therapy, 2005-
 Journal of Engineering and Regenerative Medicine, 2006-
 Stem Cells, 2007-2008
 Stem Cells International, 2008-

PATENTS:

WO9718298: Ex vivo culture of stem cells
 CA2381292: Multipotent adult stem cells and methods for isolation
 US2007022482: High-throughput functional analysis of gene expression
 WO2006086639: Vascular/lymphatic endothelial cells
 WO2006047743: Swine multipotent adult progenitor cells
 WO2005045012: Endodermal stem cells in liver and methods for isolation thereof
 WO2005003320: Neuronal differentiation of stem cells
 WO2008063675: Endodermal progenitor cells
 US2002081733: Method to prepare drug-resistant, non-malignant hematopoietic cells
 WO2004050859: Homologous recombination in multipotent adult progenitor cells
 WO9513088A1: Stroma-derived stem cell growth factors
 WO9320184: Method for culturing hematopoietic cells
 WO2002040718: Method to identify genes associated with chronic myelogenous leukemia
 AU2006304318: Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
 AU2005331534: Use of MAPC or progeny therefrom to populate lymphohematopoietic tissues
 US11/808933: High Oct3/4 MAPCs and methods therefor
 US 61/022121: Stem cell aggregates and methods for making and using
 US08/82108: Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells
 US - GB 0822483.4: Maintenance/expansion of HSCs
 US 60/690089 *: HSC Self-Renewal (CIP of US2007022482)

TRAINEES:

High School students

		Current Position
Evan Cobbs	2002-2003	U of Madison, undergraduate
Nicole Ali	2002-2004	Harvard University, undergraduate
Ricky Jones	2002-2004	CalTech, undergraduate
Sam Bjork	2003-2005	Harvard University, undergraduate

Undergraduate Students

		Current Position
Venita Chandra	1997-1998	Medical School, U of Chicago

Sarah Aldrich	2000, 2001	Medical School, U of Chicago
Aaron Lisberg	2001, 2002	MD/PhD program,
Zach Kastenber	2002-2004	Medical School, U. of Minnesota
Eric Rahrman	2002-2005	Graduate School, U of Minnesota
Lee Sandquist	2003-2005	Medical School, U of Minnesota
Juliana Hagenbrock	2003-2006	PhD Student, University of Amsterdam, The Netherlands
April Breyer	2003-2006	Law School, Boston College Law School
Jennifer Gravelle	2003-2005	Medical School, U of Minnesota
Mike Felten	2003-2005	Medical School, U of Minnesota
Thomas Szynski	2003-2005	Medical School, Harvard U

Medical Student Advisor

Sjoban Keel, B.S.	1997-1998
Troy Lund, Ph.D.	1998-2002
David Dyle, B.S.	1998-2000
Zubaid Rafique, B.S.	2003-2005
Tzu-Fei Wang, M.S.	2004-2005
Eleanor Chen, Ph.D	2004-2006

Medical Resident Research

Jade Anderson, M.D.	1999-2000
Ken Lee, M.D.	2000-2001

Medical Resident Advisor

Sjoban Keel, M.D.	2000-2001
David Dyle, M.D.	2000-2004

Masters Students

Yuehua Jiang, M.D.	1997-1999
Sofia Melikova, B.S.	2000-1002
Ben Vaessen, B.S.	2000-2002
Avinash Jayaswal, B.S.	2002-2003
Qing Cai	2006-2007
Janick Beckers	2006-2007
David Zwaenepoel	2006-2007
Adriaan Campo	2006-2007
Maria Aelberts	2007
Antonio LoNigro	2007-2008
Simone Calzolari	2007-2008
Kim Van Uytsel	2007-2008
Jasper Wouters	2007-2008
Tine Verryckt	2007-2008
Olivier Govaere	2007-2008
Lotte Vanbrabant	2007-2008
Vijay Kumar	2008
Alessandra Familiari	2008-2009
Caterina DiPrieto	2008-2009

Graduate Students:

Beverly Lundell, MS.	1993-1996
Eugene Liu, M.D.	1996-2000
Scott Dylla, M.S.	1998-2002
Fernando Ulloa, B.S	2002-2006
Lucas Chase, B.S.	2003-2006
Eric Mendenhall, B.S.	2003-2006
Lepeng Zeng, B.S.	2003-2006
Jeff Ross, B.S., M.S.	2003-2006
Ben Kidder, B.S.	2003-2007
Shannon Buckley, B.S.	2004-2009
Annelies Crabbe, BS	2006-
Valerie Roobroeck, BS	2006-

Current Position

Fellow, Hematology, U. of Washington
 Pediatric Heme-Onc Fellow, U of Minnesota
 Fellow, Genetics, U. of Washington

Pathology Residency, Harvard U

Current Position

Fellow, Hematology, U. of Minnesota
 Fellow, Cardiology, UCSF

Current Position

Fellow, Hematology, U. of Washington
 Fellow, Genetics, U. of Washington

Current Position

Assist. Prof., U of Minnesota
 Scientist, R&D Systems, Minneapolis
 Scientist, Glaxo-Smith-Kline
 Medical School, UCL, Brussels, Belgium
 PhD Student, K.U.Leuven
 PhD Student, K.U.Leuven
 Scientist, ReGenesys, BVBA
 PhD Student, U. Antwerpen
 PhD Student, U. of Copenhagen
 PhD Student, K.U.Leuven
 PhD Student, U. of Barcelona
 PhD Student, K.U.Leuven
 PhD Student, K.U.Leuven

 PhD Student, K.U.Leuven
 Technician, K.U.Leuven
 PhD Student, U of Toronto

Current Position

Scientist, Aastrom, Michigan
 Assist Prof of Medicine, U. of Taipei, Taiwan
 Post-doc, Irving Weissman, Stanford U
 Scientist, Glaxo Smith Kline
 Scientist, Invitrogen
 Post-doc, Bernstein lab, MIT
 Scientist, Medtronic
 Scientist, Surmodics
 Postdoc, Serono, Boston

Kartik Subramanian, BS	2006-
Yonsil Park, BS	2006-
Jason Owens, BS	2007-
Qing Cai, BS, MS	2007-
Kim Van Uytzel, BS, MS	2008-
Antonio LoNigro, BS, MS	2008-
Rojin Abraham MD	2008-
Elda Mineola, MD	2008-

MD/PhD students:

Morayma Reyes, B.S.	1997-2001
Robert Schwartz, B.S.	2000-2004
Craig Eckfeldt, B.S.	2002-2005
Sarah Frommer, B.S.	2002-2006
Terri Burns, B.S.	2003-2007

Current Position

Ass. Prof. Lab Medicine, U of Washington, Seattle
 Fellow Gastroenterology, Harvard University, Boston
 Resident Internal Med, U. of Minnesota
 Medical School, U of Minnesota
 Medical School, U. of Minnesota

Postdoctoral Fellows

Chunjin Ding, M.D.	1992-1994
Huillin Qi, Ph.D.	1998-2003
Dean Aguiar, Ph.D.	1999-2001
Yuehua Jiang, MS, MD	1999-2002
Stephanie Salesse, Ph.D.	2000-2005
Mo Dao, Ph.D.	2001-2004
Troy Lund, MD, Ph.D.	2002-2003
Yves Heremans, Ph.D.	2002-2005
Uma Lakshminpathy, Ph.D.	2002-2005
Beatrice Pelacho, Ph.D.	2002-2005
Aernout Luttun, Ph.D.	2002-2006
Miguel Barajas, Ph.D.	2004-2006
Marta Serafini, Ph.D.	2004-2006
Rik Snoeckx, Ph.D.	2005-2009
Kris Van den Boogaert, Ph.D.	2005-
Carlos Clavel, Ph.D.	2005-2008
Fernando Ulloa, Ph.D.	2006-2008
Martine Geeraerts, Ph.D.	2006-
Pau Sancho-Bru, Ph.D.	2007-2009
Takeshi Shimizu, Ph.D.	2007-
Jeroen DeClercq, Ph.D.	2007-
Bipasha Bose, Ph.D.	2008-2009
Anujit Kumar, Ph.D.	2008-
Satish Kumar, Ph.D.	2009-
Yong Li, Ph.D.	2008-

Scientist, Ely Lilly, Indianapolis
 Scientist, Yale University
 Staff Scientist, Pharmacia
 Assist. Prof., U of Minnesota
 Assist. Prof, U of Reims, France
 Post Doc, N Taylor, Montpellier, France
 Assist. Prof, Department of Pediatrics, U of Minnesota
 Instructor VUB, Belgium
 Staff Scientist, Invitrogen, CA
 Instructor, U of Navarra, Pamplona, Spain
 Assist. Prof, K.U.Leuven, Belgium
 Assist. Prof., U of Navarra, Pamplona, Spain
 Assist. Prof., Fondazione M.Tettamanti M.De Marchi
 Onlus, Monza, Italy
 Postdoctoral fellow, J Cools lab, VIB-KULeuven

 Postdoc, Einstein University, USA
 Scientist, Glaxo Smith Kline

Fellows

Jeffrey S Miller, M.D.	1991-1994
Pankaj Gupta, M.D.	1992-1995
Randolph Hurley, M.D.	1992-1995
Ravi Bhatia, M.D.	1992-1996
K.Y. Chiang, M.D., Ph.D.	1993-1995
Vivek Roy, M.D.	1994-1996
Robert Zhao, M.D., Ph.D	1995-1998
Michael Punzel, M.D.	1996-1998
Felipe Prosper, M.D.	1995-1997
Michel Delforge, M.D.	1995-1996
Juliet Barker, M.D.	1997-1999
Ian Lewis, M.D., Ph.D.	1997-1999
Chris Lamming, M.D.	1999-2002
Claudio Brunstein, M.D.	1999-2002

Current Position

Prof. of Medicine, Director, Translational Research
 Program, Cancer center, U. of MN
 Prof. of Medicine, U. of MN
 Staff Physician, Health Partners, St Paul, MN
 Prof. of Medicine, Director Stem Cell Program, City of Hope
 Assist Prof. Pediatrics, Emory University, Atlanta GA
 Assist. Prof. of Medicine, Mayo Clinic, FL
 Professor, Professor, Chinese Acad. of Sci. & Peking
 Union Medical College
 Assoc Prof., U. of Duesseldorf, Germany
 Prof. of Medicine and Director Stem Cell Program, U. of
 Navarra, Pamplona, Spain
 Assoc. Prof, KULeuven, Belgium
 Assoc. Prof. of Medicine, Sloan Kettering Institute, NYC
 Assoc. Prof. of Medicine, U. of Adelaide, Australia
 Pediatric Fellow, Baylor College, Houston, TX
 Assist Prof. of Medicine, U of Minnesota

Koen Theunissen, M.D.	1999-2001	Hematologist, Virga Jesse Hospital, Hasselt
Balkrishna Jahagirdar, M.D.	2000-2002	Assist Prof. of Medicine, U of Minnesota
Eugene Liu, M.D., Ph.D.	2000-2002	Assist Prof. of Medicine, U. of Taipei, Taiwan
Mojca Jongen, M.D.	2001-2003	Instructor Hematology, U. of Rotterdam, NL
Anskar Leung, M.D., Ph.D.	2001-2003	Assist. Prof, U of Honk-Kong
Masayuki Oki, M.D.	2003-2006	Assist. Prof, Tokai U, Tokio, Japan
Catherine Flynn, M.D.	2004-2007	Consultant Haematologist, St James's Hospital and Coombe Women's Hospital, Dublin
Karen Pauwelyn, M.D.	2005-2009	Fellow, Hepatology, K.U.Leuven
Helene Schoemans, M.D.	2006-2008	Fellow, Hematology, K.U.Leuven
Philip Roelandt, M.D.	2007-	

INVITED LECTURES (Since 2007)

2007

Keynote Speaker, Basel Switzerland
 First Connecticut International Stem Cell Symposium, Hartford, CT
 Grand Challenge Meeting 4, Lugano, Switzerland
 Symposium on tissue reconstruction, UCL, Brussels, Belgium
 8th Advanced Summer Course in Cell - Materials Interactions, Instituto de Engenharia Biomédica, Porto, Portugal
 MSC2007, Adult Mesenchymal Stem Cells in Regenerative Medicine, Cleveland, OH
 The Second UK Mesenchymal Stem Cell Meeting, U of York, Great Britain
 International Symposium "Stem cells, Development and Regulation" Amsterdam, The Netherlands
 Symposium on Cardiovascular Regenerative Medicine, NIH, Washington DC, USA
 Spanish National Congress of Surgery, San Sebastian, Spain
 Scottish Stem Cell Network, Glasgow, Scotland
 Interhospital Endocrine Rounds, Montreal, Canada
 Research Seminar, Buck Institute, CA
 Research Seminar, U Liege, Belgium
 Research Seminar, VUB, Brussel

2008

Keynote Lecture, EPISTEM conference, Gent, Belgium
 Keynote Lecture, VIB, Blankenberge, Belgium
 Keynote Lecture, Italian Society for Biotechnology and Medical Engineering, Rieti, Italy
 Keynote Lecture, Wadden Symposium on Diabetes, Texel, the Netherlands
 Keynote Lecture, Annual Norwegian Stem Cell Network, Oslo Norway
 Keynote Lecture, Itera Conference, Maastricht, the Netherlands
 Keynote Lecture, Annual science day of the GROW, Maastricht, The Netherlands
 EuroSTELLS, Stem Cell Niche Meeting, Barcelona, Spain
 Symposium "Pluripotency and differentiation in embryos and stem cells", Pavia, Italy
 The Adult Stem/Progenitor Cell Niche, Brussels, Belgium
 Nederlandse Vereniging voor Hematologie, Papendal, the Netherlands
 Annual Wound Healing Society Meeting, San Diego, USA
 International Stem Cell Meeting, Tel Aviv, Israel
 EAE/ESH 2nd symposium on MSC, Mandelieu, France
 Summer School, Barsinghaue, Germany
 Nobel Forum Cancer Stem Cell Conference, Stockholm, Sweden
 4th International Conference on Regenerative Hepatology, Dusseldorf, Germany
 European Society of Gene Therapy, Brugge, Belgium
 Mayo Clinic Stem Cell and Regeneration Symposium, Rochester, MN, USA
 The 5th Dubai International Conference for Medical Sciences, Dubai
 EU-EPC Roundtable, Brussels Belgium

2009

Plenary Lecture, Annual Meeting, French Society of Blood Transfusion, Strasbourg, France
 Plenary Lecture, Annual Meeting, ESGT, Hannover, Germany
 The Sanquin Spring Seminar, Amsterdam, the Netherlands
 Flanders Bio Seminar Tissue Engineering, Brussels
 Research Seminar, UCL, Brussels, Belgium
 Research Seminar, U Frankfurt, Frankfurt, Germany
 Epiplasticarcinoma Marie Curie RTN network meeting, Leuven, Belgium

MEETING ORGANIZER

Yearly Meeting ISEH, 2005, Glasgow, Scotland

Yearly meeting ISEH, 2006, Minneapolis, MN

Keystone meeting, Stem Cells, 2006, Whistler, Canada

Mesenchymal Stem Cells (1), 2006, Mandelieu, France

Mesenchymal Stem Cells (2), 2008, Mandelieu, France

Muscular Dystrophy Symposium Leuven, October 2, 2008

Stem Cells: Biology and Applications; Sponsored by FP6-STROKEMAP and TEFAF, Leuven, 2009

RESEARCH INTERESTS:

1. NORMAL HEMATOPOIESIS:

- Regulation of normal human hematopoietic stem cell proliferation, differentiation and lineage commitment by cytokines and components of the extracellular matrix using *in vitro* as well as *in vivo* xenogeneic transplant models.
- Molecular characterization of hematopoietic stem cells by functional genomics, and zebrafish model of hematopoiesis

2. PLURIPOTENT STEM CELLS (MAPC, ESC, iPS).

- Purification, expansion and characterization of differentiation to mesodermal, ectodermal and endodermal lineages
- Characterization of molecular determinants of pluripotent and multipotent stem cell phenotype, and of differentiation and differentiation
- Evaluation of therapeutic potential in congenital disorders or for the treatment of vascular, neurodegenerative disorders, hepatic disorders and diabetes.

CURRENT FUNDING:

- **PO1-CA-65493-06 (PI P McGlave):** Biology and Transplantation of Human Stem cells Project Period: 7/1/2000 - 6/30/2005. Project Leader: project 1; Annual Direct Cost: \$210,000/year
- **FWO (PI Verfaillie)** Het potentieel van multipotente adulte progenitor cellen in de vervanging van insuline-secreterende β -cellen in preklinische modellen van type 1 diabetes. Period 1/1/2007-12/31/2009; annual direct cost: €30,000
- **KUL CoE (PI Verfaillie)** Period: 11/1/2005 - 10/31/2009. Annual Direct Cost: €500,000/year
- **Odysseus Fund (PI Verfaillie)** Period: 12/21/2006 - 12/31/2010. Annual Direct Cost: €1,390,000/year
- **FP6-STREP: STROKEMAP (PI Verfaillie).** Multipotent Adult Progenitor Cells to treat Stroke; Period: 10/1/2006 - 9/30/2009. Total Cost: €2,400,000; Total cost Verfaillie €420,000
- **FP6-STREP: CRYSTAL, (partner 6: Verfaillie)** Cryobanking of stem cells for human clinical application. Period: 1/1/2007 - 12/30/2009. Total cost Verfaillie: €321,000
- **SBO BRAINSTIM (PI Verfaillie);** non-invasive imaging of stem cells in the brain; Period 10/1/2007-9/31/2011; Total Cost: €2,650,000; Total cost Verfaillie €550,000
- **SBO: IMAGINE (Partner Verfaillie).** Generation of improved paramagnetic particles for stem cell labeling and application in tumor therapy. Period: 1/1/2009 - 12/31/2013. Total cost Verfaillie: €250,000

PENDING FUNDING:

- **FP7: BELISTEM (Partner Verfaillie).** Stem cells suitable for liver regeneration. From the bench to the bed side; Period: 1/1/2010 - 12/30/2014. Total cost partner Verfaillie: €1,100,000
- **FP7: STEMPEP (Partner Verfaillie).** Stem cells suitable for therapy of peripheral vascular disease. Period: 1/1/2010 - 12/30/2014. Total cost KULeuven: €1,300,000
- **SBO: HEPSTEM (PI Verfaillie).** Generation of mature hepatocytes from human induced pluripotency stem cells Period: 1/1/2010 - 12/31/2014. Total cost €2,500,000
- **NIH GRANT 10121990 (PI Ekker, Co-I Verfaillie).** Genomic Analysis of Hematopoietic Stem Cell Niche Formation, Maintenance & Function. Period: 1/7/2009 – 30/6/2014. Yearly Budget Verfaillie: \$125,000
- **Dutch Diabetes Fund (PI P Devos, Co-I Verfaillie).** Human fetal and adult progenitor cells as a source for insulin producing cells. 4/1/2009 - 31/3/2012. Total cost Verfaillie €250,000

BIBLIOGRAPHY:

1. Goovaerts J, Verfaillie C. Effect of Prenalterol on orthostatic hypotension in the Shy-Drager syndrome. Brit Med J 288: 817-819, 1984. (IF: 9.1)
2. Goovaerts J, Verfaillie C. Prenalterol in the treatment of orthostatic hypotension in the Shy-Drager syndrome. Acta Cardiologica 2: 147-155, 1984. (IF: 0.4)
3. Rummens J, Verfaillie C. Capnocytophaga infections: a risk in the immunocompromised host. Acta Clinica Belgica 39: 2-10, 1984. (IF: 0.58)
4. Louwagie A, Criel A, Verfaillie C. Philadelphia chromosome positive T acute lymphoblastic leukemia. Cancer Genet and Cytogenet 16: 297-300, 1985. (IF: 1.57)

5. Rummens JL, Verfaillie C, Criel A, Hidajat M, Vanhoof A, Van den Berghe H, Louwagie A. Elliptocytosis and schistocytosis in myelodysplasia: report of two cases. *Acta Haematologica*. 75:174-7, 1986. (IF: 1.3)
6. Verfaillie CM, Miller W, Kay N, McGlave P. Adherent Lymphokine Activated Killer (ALAK) cells in chronic myelogenous leukemia: A benign cell population with potent cytotoxic activity. *Blood* 74: 793-798, 1989. (IF: 10.9)
7. Verfaillie CM, Miller W, Kay N, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompanies disease progression in chronic myelogenous leukemia. *Blood* 76: 401-408, 1990. (IF: 10.9)
8. Verfaillie CM, Blakolmer K, McGlave P. Purified primitive hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. *J Exp Med* 172: 509-520, 1990. (IF: 15.6)
9. Verfaillie CM, McGlave P. Leukemia inhibitory factor (LIF)/human interleukin for DA cells (HILDA) supports the growth of multipotential hematopoietic cells in vitro. *Blood* 77: 263-270, 1991. (IF: 10.9)
10. Miller JS, Verfaillie CM, McGlave PB. Adherent lymphokine-activated killer (A-LAK) cells suppress autologous human normal bone marrow progenitors. *Blood* 77: 2389-2395, 1991. (IF: 10.9)
11. Verfaillie CM, Weisdorf D, Haake R, Hostetter P, Ramsay NKC, McGlave P. Candida infections in bone marrow transplant recipients. *Bone Marrow Transplant* 8:177-184, 1991. (IF: 2.6)
12. Verfaillie CM, McCarthy JB, McGlave PB. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. *J Exp Med* 174: 693-703, 1991. (IF: 15.6)
13. Uhlman D, Verfaillie C, Jones RB, Luikaert SD. BCNU treatment of marrow stromal layers reversibly alters hematopoiesis. *Brit J Hemat* 78:304-309,1991. (IF: 4.1)
14. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. *Blood* 79: 1003-1011, 1992. (IF: 10.9)
15. Verfaillie CM. Direct contact between progenitors and stroma is not required for human in vitro hematopoiesis. *Blood* 79: 2821-2826, 1992. (Rapid communication) (IF: 10.9)
16. Verfaillie CM, McCarthy JB, Miller WJ, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. *J Clin Invest* 90: 1232-1329, 1992. (IF: 16.9)
17. Miller JS, Oelkers S, Verfaillie C, McGlave P. The role of monocytes in the expansion of human activated natural killer cells. *Blood* 80: 2221-2226, 1992. (IF: 10.9)
18. Miller JS, Verfaillie C, McGlave PB. The generation of natural killer cells from CD34+/DR- primitive progenitors in human long-term bone marrow culture. *Blood* 80: 2182-2187, 1992. (Rapid communication) (IF: 10.9)
19. Verfaillie CM. Soluble factor(s) produced by human bone marrow stroma increase cytokine induced proliferation and maturation of primitive human hematopoietic progenitors while preventing their terminal differentiation. *Blood* 82:2045-2054, 1993. (IF: 10.9)
20. McGlave PB, Verfaillie CM, Miller JS Interaction of human myeloid and lymphoid progenitors with the marrow microenvironment. *Blood Cells* 20: 121-128, 1994 (IF: 2.78)
21. Verfaillie CM, Catanzarro P, Lin W-N. MIP-1 α combined with IL3 conserves primitive human LTBMIC for at least 8 weeks in ex vivo "stroma-non-contact" cultures. *J Exp Med* 179: 643-649, 1994. (Rapid communication) (IF: 15.6)
22. Pierson BA, Miller JS, Verfaillie C, McGlave PB, Hu W-S. Population dynamics of human activated killer cells in culture. *Biotech Bioengineering* 43: 685-692, 1994
23. Bhatia R, Wayner E, McGlave P, Verfaillie CM. Interferon- α restores adhesion of malignant progenitors in CML by restoring β 1 integrin function. *J Clin Invest* 94: 384-391, 1994. Comment in: *J Clin Invest*: 94: 3, 1994 (IF: 16.9)
24. Burroughs JM, Gupta P, Verfaillie CM. Soluble factors from the mouse fibroblast cell line M210-B4 support in vitro hematopoiesis. *Exp Hematol* 22:1095-1101,1994. (IF: 3.11)
25. Verfaillie CM, Miller JS. CD34+/CD33- cells reselected from MIP-1 α +IL3 supplemented "stroma-non-contact" cultures are highly enriched for LTBMIC. *Blood* 84:1442-1450, 1994. (IF: 10.9)
26. Verfaillie CM, Benis A, Iida G, McGlave PB, McCarthy J. Adhesion of committed human hematopoietic progenitors to synthetic peptides in the C-terminal heparin-binding domain of fibronectin: cooperation between the integrin α 4 β 1 and the CD44 adhesion receptor. *Blood* 84: 1802-1812, 1994. (IF: 10.9)
27. Weisdorf D, Katsanis E, Verfaillie C, Ramsey NKC, Haake R, Garrison L, Blazar BR. IL-1 α administered after autologous transplantation: a phase I clinical trial. *Blood* 84: 2044-2049, 1994. (IF: 10.9)
28. Miller JS, Klingsporn S, Lung J, Perry E, Verfaillie CM, McGlave PB. Large scale generation of activated natural killer cells. *Bone Marrow Transplant* 14: 789-792, 1994. (IF: 2.6)
29. Low WC, Eastlund T, Verfaillie C, Hirschel M, Virnig B, Weese K, Norris B, Chrysler G, Peterson A, Forbes J. Human fetal tissue from spontaneous abortions as potential sources of donor tissue for cell transplantation Therapy. *Transplant. Proc* 26: 3500-5, 1994. (IF: 0.5)
30. Yuh DD, Kubo SH, Francis GS, Bank A, McDonald KM, Jessurun J, Verfaillie C, Shumway SJ. Primary cardiac lymphoma treated with heart transplantation: an orthoptic case report. *J. Heart & Lung Transplant* 13: 538-42, 1994. (IF: 1.4)

31. Evenson DA, Stroncek DF, Pulkrabek S, Perry EH, Radford J, Miller JS, Verfaillie C. Post Transplant Purpura Following Bone Marrow Transplantation. *Transfusion* 35: 688-93, 1995. (IF: 3.7)
32. Greeno E, Haake R, Weisdorf D, McGlave P, Verfaillie C. Lupus inhibitors in bone marrow transplant recipients. *Bone Marrow Transplantation* 15: 287-291, 1995. (IF: 2.6)
33. Weisdorf DJ, Verfaillie CM, Davies SM, Fillipovich AH, Wagner JE, Miller JS, Burroughs J, Ramsay NKC, Kersey JH, McGlave PB, Blazar BR. Hematopoietic growth factors for graft failure following bone marrow transplantation: a randomized trial of GM-CSF versus sequential GM-CSF plus G-CSF. *Blood* 85:3452-3459, 1995. (IF: 10.9)
34. Bathia R, Dewald G, McGlave P, Verfaillie CM. Abnormalities of the bone marrow microenvironment in chronic myelogenous leukemia are related to malignant macrophages. *Blood* 85: 3636-3645, 1995. (IF: 10.9)
35. Hurley RW, McCarthy JB, Verfaillie CM. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. *J Clin Invest* 96: 511-9, 1995. (IF: 16.9)
36. Bhatia R, McGlave PB, Verfaillie CM. Interferon- α treatment of normal bone marrow stroma results in enhanced adhesion of CML hematopoietic progenitors via mechanisms involving MIP-1 α . *J Clin Invest* 96: 931-9, 1995. (IF: 16.9)
37. Verfaillie CM, Miller JS. A novel single cell proliferation assay demonstrates that LTC-IC maintenance over time results from the proliferation of a small fraction of LTC-IC. *Blood* 86: 2137-2145, 1995. (IF: 10.9)
38. Roy V, Verfaillie CM. Refractory Thrombocytopenia Due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation-case report and review of the literature. *Bone Marrow Transplant* 17: 115-7, 1996. (IF: 2.6)
39. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM. Adhesion to fibronectin (FN) induced by the activating anti-integrin- β 1 antibody, 8a2, restores adhesion mediated inhibition of CML progenitor proliferation. *Blood* 87: 2450-8, 1996. (IF: 10.9)
40. Cervantes P, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long term culture. *Blood* 87: 2476-85, 1996. (IF: 10.9)
41. Gupta P, McCarthy JB, Verfaillie CM. Marrow stroma derived proteoglycans combined with physiological concentrations of cytokines are required for LTC-IC maintenance. *Blood* 87: 3229-36, 1996. (IF: 10.9)
42. Bhatia R, McCarthy JB, Verfaillie CM. Interferon- α restores normal β 1-integrin mediated negative regulation of chronic myelogenous leukemia progenitor proliferation. *Blood* 87: 3883-91, 1996. (IF: 10.9)
43. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Stiegelbauer K, Dewald G, Miller JS, McGlave PB. Benign primitive progenitors can be selected on the basis of the CD34⁺/HLA-DR⁻ phenotype in early chronic phase but not advanced phase CML. *Blood* 87: 4770-9, 1996. (IF: 10.9)
44. Verfaillie CM, Catanzarro P. Development of a novel single LTC-IC proliferation assay that can determine the fate of LTC-IC over time. *Leukemia* 10: 498-504, 1996. (IF: 6.9)
45. Enright H, Davies, SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NKC, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P. Relapse following non-T-cell depleted allogeneic bone marrow transplant for CML: early transplant, the use of an unrelated donor and chronic graft-versus-host disease are protective. *Blood* 88: 714-20, 1996. (IF: 10.9)
46. Prosper F, Stroncek D, Verfaillie CM. Phenotypic and functional characterization of long-term culture initiating cells (LTC-IC) present in peripheral blood progenitor collections of normal donors treated with G-CSF. *Blood* 88: 2033-42, 1996. (IF: 10.9)
47. Hurley R, McCarthy JB, Verfaillie CM. Clustering of integrins results in proliferation inhibition of committed hematopoietic progenitors through mechanisms involving the cell cytoskeleton. *Exp Hematol* 25:321-8, 1997. (IF: 3.1)
48. Roy V, Miller JM, Verfaillie CM. Phenotypic and functional characterization of progenitors with myeloid and lymphoid differentiation potential in human fetal liver. *Exp Hematol* 25: 387-94, 1997. (IF: 3.1)
49. RH Collins, Shpilberg O, Drobyski WR, Porter D, Giral S, Champlin R, Goodman SA, Wolf SN, Hu W, Verfaillie CM, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Neumanitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. *J Clin Oncol* 15: 433-44, 1997. (IF: 11.8)
50. Prosper F, Stroncek D. Verfaillie CM. Expansion of primitive LTC-IC from G-CSF mobilized peripheral blood progenitor cells (PBPC). *Blood* 89: 3991-7, 1997. (IF: 10.9)
51. Weisdorf DJ, Verfaillie CM, Miller WJ, Blazar BR, Perry E, Shu XO, Daniels K, Hannan P, Ramsay NKC, Kersey JH, McGlave PB. Autologous bone marrow versus peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial. *Am J Hematol* 54: 202-8, 1997. (IF: 1.7)
52. Bhatia R, McGlave PB, Wissink S, Miller JS, Wissink S, Verfaillie CM. A large-scale clinical expansion culture for primitive myeloid and lymphoid progenitors and committed clonogenic cells using stroma conditioned medium and cytokines. *Exp Hematol* 25: 980-91, 1997. (IF: 3.1)
53. Roy V, Verfaillie CM. Soluble Factor(s) produced by adult bone marrow stroma inhibit proliferation and differentiation of fetal liver BFU-E in vitro by inducing apoptosis. *J Clin Invest* 100: 912-20, 1997. (IF: 16.9)
54. Miller JS, Tessmer-Tuck J, Pierson B, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie CM, Lebkowski J, Radford J, Burns LJ. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. *Biol Blood Marrow Transplantation* 3:34-44, 1997. (IF: 3.27)

55. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM. Activation of $\beta 1$ -integrins on CML progenitors reveals cooperation between $\beta 1$ -integrins and CD44 in regulation of adhesion and proliferation. *Leukemia* 11: 822-29, 1997 (IF: 6.9)
56. Billadeau D, Prosper F, Verfaillie CM, Weisdorf D, Van Ness B. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement. *Leukemia* 11: 1565-70, 1997. (IF: 6.9)
57. Weisdorf D, Miller JS, Verfaillie CM, Burns L, Wagner J, Blazar B, Davies S, Miller W, Hannan P, Steinbuch M, Ramsay N, McGlave P. Cytokine primed marrow stem cells versus peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF and G-CSF. *Biol Blood Marrow Transplant* 3: 217-223, 1997. (IF: 3.27)
58. Zhao RC, Mclvor RS, Griffin JD, Verfaillie CM. Elimination of tumorigenicity of BCR/ABL positive cells in vivo by a retroviral vector containing an anti-BCR/ABL antisense sequence and confers methotrexate resistance. *Blood* 90: 4687-98, 1997. (Rapid communication) (IF: 10.9)
59. Lutarewych MA, Quirck MR, Kringstad BA, Li W, Verfaillie CM, Jordan MC. Propagation and titration of murine cytomegalovirus in a continuous marrow derived stromal cell line (M2-10B4). *Virol Methods* 68:193-8, 1997.
60. Verfaillie CM, Bhatia R, Brown P, Key N. Interferon-alpha restores $\beta 1$ -integrin dependent, collagen mediated platelet aggregation in a patient with chronic myelogenous leukemia *J Lab Clin Med* 136: 163-169, 1998 (IF: 1.8)
61. Gupta P, Blazar BR, Verfaillie CM. Human CD34⁺ hematopoietic cells regulate stromal production of interleukin-6 and granulocyte-colony-stimulating factor which increases their proliferation and differentiation. *Blood* 91: 3724-33, 1998 (IF: 10.9)
62. Bhatia R, Verfaillie CM. Inhibition of BCR/ABL expression by anti-sense oligonucleotides normalizes $\beta 1$ -integrin mediated adhesion and regulation of proliferation in chronic myelogenous leukemia. *Blood* 91: 3414-22, 1998. (IF: 10.9)
63. Miller JS, McKullar V, Verfaillie CM. Ex vivo culture of CD34⁺Lin⁻DR⁻ cells in stroma-derived soluble factors, IL3 and MIP-1 α maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay. *Blood* 91: 4516-22, 1998. (IF: 10.9)
64. Prosper F, McCarthy JD, Stroncek D, Verfaillie CM. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of $\alpha 4\beta 1$ -integrin expression and function. *J Clin Invest* 101: 2456-67, 1998. (IF: 16.9)
65. Verfaillie CM, Bhatia R, Steinbuch M, DeFor T, Hirsch E, Miller JS, Weisdorf D, McGlave PB. Comparative analysis of autografting in CML: effect of mobilization regimen and marrow or blood origin of cells. *Blood* 92: 1820-31, 1998. (IF: 10.9)
66. Bhatia R, Munthe H, Verfaillie CM. The BCR/ABL specific tyrosine kinase inhibitor, tyrphostin AG975, restores $\beta 1$ -integrin mediated adhesion and signaling in CML hematopoietic progenitors. *Leukemia* 12: 1708-17, 1998. (IF: 6.9)
67. Gupta P, Oegema TR, Verfaillie CM. Differences in the LTC-IC maintaining capacity of stromal cells correlates with patterns of sulfation of their heparan sulfate glycosaminoglycans. *Blood* 92:4641-51, 1998. (IF: 10.9)
68. Roy V, McCarthy JM, Verfaillie CM. Differences in adhesion receptor expression and function between hematopoietic progenitors from fetal liver, umbilical cord blood and adult marrow. *Exp Hematol* 27: 1-11, 1999. (IF: 3.1)
69. Delforge M, Boogaerts M, McGlave PB, Verfaillie CM. CD34⁺HLA-DR⁻ cells in chronic phase CML, but not in more advanced phase CML, are polyclonal. *Blood* 93: 284-292, 1999. (IF: 10.9)
70. Punzel M, Moore KA, Lemishka IR, Verfaillie CM. The type of stromal feeder used in limiting dilution assays influences frequency and maintenance assessment of human long-term culture initiating cells. *Leukemia* 131:92-7, 1999. (IF: 6.9)
71. Punzel M, Wissink S, Aselson K, Miller JS, Lemishka IR, Moore KA, Verfaillie CM. Development of an *in vitro* assay that can enumerate Myeloid-Lymphoid Initiating Cells (ML-IC) in adult human bone marrow. *Blood* 93: 3750-3756, 1999. (IF: 10.9)
72. Punzel M, Gupta P, Verfaillie CM. Factors secreted by AFT024 fetal liver cells following stimulation with human cytokines are important for human LTC-IC growth. *Leukemia*, 131079-84, 1999. (IF: 6.9)
73. Bhatia R, Munthe H, Verfaillie CM. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. *Exp Hematol*. 27:1384-96, 1999. (IF: 3.1)
74. Gupta P, Dudek A, Slungaard A, Oegema T, Verfaillie CM. 6-O-sulfated heparin enhances IL3+MIP-1 α mediated expansion of LTC-IC in stroma-free cultures. *Blood* 95:147-55, 2000. (IF: 10.9)
75. Jiang Y, Prosper F, Verfaillie CM. Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors. *Blood*. 95:846-54, 2000. (IF: 10.9)
76. Liu HJ, Hung Y, Wissink SD, Verfaillie CM. Improved retroviral transduction of hematopoietic progenitors by combining methods to enhance virus-cell interaction. *Leukemia* 14:307-11, 2000. (IF: 6.9)
77. Barker J, Verfaillie CM. Generation of mature B cells from human adult pro B cells: a novel in vitro model of B cell lymphopoiesis. *Leukemia*. 14:1614-20, 2000. (IF: 6.9)

78. Jiang Y, Zhao RCH, Verfaillie CM. Inactivation of the cyclin-dependent kinase inhibitor, p27, is responsible for overriding the integrin-mediated inhibition of CML CD34⁺ cells. *Proc Natl Acad Sci U S A* 97:10538-10543, 2000. (IF: 9.6)
79. Verfaillie CM, Almeida-Porada G, Wissink S, Zanjani ED. Short- and long-term engraftment of CD34⁺ and CD34⁺ cells from mobilized blood differs from that of CD34⁺ and CD34⁺ cells from bone marrow. *Exp. Hematol.* 28:1071-9, 2000. (IF: 3.1)
80. Lewis I, Verfaillie CM. Differential culture requirements for the expansion of umbilical cord and mobilized blood myeloid and lymphoid progenitors. *Exp. Hematol.* 28:1087-95, 2000. (IF: 3.1)
81. Lickliter JD, McGlave PB, DeFor TE, Miller JS, Ramsay NK, Verfaillie CM, Burns LJ, Wagner JE, Eastlund T, Dusenbery K, Weisdorf DJ. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation. *Bone Marrow Transplant*, 26:723-8, 2000. (IF: 2.6)
82. Brunstein CG, Hirsch BA, Miller JS, McGlennen RC, Verfaillie CM, McGlave PB, Weisdorf DJ. Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission before eventual relapse. *Bone Marrow transplant* 26: 1173-1177, 2000. (IF: 2.6)
83. Ballen K, Broxmeyer HE, McCullough J, Piaciabello W, Rebulla P, Verfaillie CM, Wagner JE. Current status of cord blood banking and transplantation in the United States and Europe. *Biol Blood Marrow Transplant.* 7:635-45, 2001. (IF: 3.2)
84. Jahagirdar B, Shet A, Miller JS, Verfaillie CM. Novel targeted therapies for CML. *Exp Hematol.* 29:543-56, 2001. (IF: 3.1)
85. Lewis ID, Du J, Almeida-Porada J, Zanjani ED, Verfaillie CM. Long-term repopulating cord blood stem cells are preserved after ex-vivo culture in a non-contact system *Blood* 97:3441-9, 2001. (IF: 10.9)
86. Davies SM, DeFor TE, McGlave PB, Miller JS, Verfaillie CM, Wagner JE, Weisdorf DJ. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. *Am J Med.* 110:339-46, 2000. (IF: 4.27)
87. Zhao RCH, Jiang Y, Verfaillie CM. A model of human p210^{BCR/ABL} mediated CML by transducing primary normal human CD34⁺ cells with a BCR/ABL containing retroviral vector. *Blood* 97:2406-12, 2001. (IF: 10.9)
88. Reyes M, Dudek A, B. Jahagirdar, Koodie L, Verfaillie CM. Origin of endothelial progenitors in human post-natal bone marrow *J Clin Invest.* 109: 337-346, 2002. (IF: 16.9)
89. Sweeney CL, Diers MD, Frandsen JL, Gunther R, Verfaillie CM, Mclvor RS. Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia. *J Pharmacol Exp Ther.* 300:1075-84, 2002. (IF: 3.49)
90. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. *Exp Neurol.* 174:11-20, 2002. (IF: 3.76)
91. Liu H, Verfaillie CM. Myeloid-lymphoid initiating cells (ML-IC) are highly enriched in the Rhodamin^c-Kit⁺CD33⁺ CD38⁺ fraction of umbilical cord CD34⁺ cells. *Exp Hematol* 30:582-9, 2002. (IF: 3.1)
92. Schwartz RE, Reyes M, Koodie, Jiang Y, Blackstad M, Johnson S, Lund T, Lenvik T, Hu W-S, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. *J Clin. Invest.* 109, 1291-1302, 2002. (IF: 16.9)
93. Lenvik T, Lund T. Verfaillie CM. Blockerette-ligated capture T7 amplified RT-PCR a new method for determining flanking sequences. *Mol. Therapy*, 6: 113-8, 2002. (IF: 5.44)
94. Jiang Y, Jahagirdar B, Reinhard L, Schwartz RE, Keene CD, Ortiz X, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 418:41-9, 2002. (IF: 26.8)
95. Brunstein CG, Hirsch BA, Hammerschmidt D, McGlennen RC, Nguyen PL, Verfaillie CM. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant. *Bone Marrow Transplant.* 29: 999-1003, 2002. (IF: 2.6)
96. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from post-natal murine bone marrow, muscle and brain. *Exp Hematol*, 30: 896-904, 2002. (IF: 3.1)
97. Punzel M, Gupta P, Verfaillie CM. The microenvironment of AFT024 cells maintains primitive human hematopoiesis by counteracting contact mediated inhibition of proliferation. *Cell Commun Adhes.* 9:149-59, 2002. (IF: 2.4)
98. Gupta S, Verfaillie C, Chmielewski D, Kim Y, Rosenberg ME. A role for extrarenal cells in the regeneration following acute renal failure. *Kidney Int* 62:1285-90, 2002. (IF: 4.7)
99. Sweeney CL, Frandsen JL, Verfaillie CM, Mclvor RS. Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. *Cancer Res* 63:1304-10, 2003. (IF: 7.7)
100. Lamming C, Blackstad M, Augustin L, Lund TC, Hebbel RP, Verfaillie CM. Spontaneous circulation of myeloid-lymphoid-culture-initiating cells and SCID repopulating cells in Sickle Cell Crisis, *J Clin Invest* 111:811-9, 2003. (IF: 16.9)
101. Qi H, Aguiar DJ, Williams SM, La Pean A, Pan W, Verfaillie CM. Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells. *Proc Natl Acad Sci U S A* 100:3305-10, 2003. (IF: 9.6)
102. Salesse S, Verfaillie CM. BCR/ABL-mediated Increased Expression of Multiple Known and Novel Genes That May Contribute to the Pathogenesis of Chronic Myelogenous Leukemia. *Mol Cancer Ther* 2:173-82, 2003. (IF: 5.2)

103. Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet Factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. *Blood* 101:4687-94, 2003. (IF: 10.9)
104. Keene CK, Ortiz-Gonzalez XR, Jiang Y, Largaespada DA, Verfaillie CM, Low WC. Neural differentiation and incorporation of bone marrow-derived multipotent adult progenitor cells after single cell transplantation into blastocyst stage mouse embryos. *Cell Transplant* 12:201-13, 2003. (IF: 3.5)
105. Guo, X., Qi, H., Verfaillie, C.M. and Pan, W. Statistical significance analysis of longitudinal gene expression data. *Bioinformatics* 19, 1628-1635, 2003. (IF: 6)
106. Dahl E, Burroughs J, DeFor T, Verfaillie C, Weisdorf D. Progenitor content of autologous grafts: mobilized bone marrow vs. mobilized blood. *Bone Marrow Transplant* 32:575-80, 2003. (IF: 2.6)
107. Jiang Y, Henderson D, Blackstad M, Chen A, Miller RF, Verfaillie CM. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. *Proc Natl Acad Sci U S A* 100:11854-60, 2003. (IF: 9.6)
108. Zhao LR, Duan WM, Reyes M, Verfaillie CM, Low WC. Immunohistochemical identification of multipotent adult progenitor cells from human bone marrow after transplantation into the rat brain. *Brain Res Protoc*. 11:38-45, 2003. (IF: 2.8)
109. Dawson, L., Bateman-House, AS, Mueller Agnew, D, Bok, H, Brock, DW, Chakravarti, A, Greene, M, King, PA, Stephen J. O'Brien, Sachs, DH, Schill, KE, Siegel, A, Solter, D., Sonia M. Suter, J.D., Verfaillie, CM, Walters, LRB, Gearhart, JD, Faden, RR. Safety issues in cell-based intervention trials. *Fertility and Sterility* 80, 1077-85, 2003 (IF: 3.1)
110. Faden RR, Dawson L, Bateman-House AS, Mueller-Agnew D, Bok H, Brock DW, Chakravarti, Gao XJ, Greene M, Hansen JA, King PA, O'Brien SJ, Sachs DH, Shill KE, LeRoy A, Solter D, Suter SM, Verfaillie CM, Gearhardt JD. Public Stem cell Banks: considerations of justice in stem cell research and therapy. *Hastings Cent Rep* 33:13-27, 2003.
111. Salesse S, Dylla S, Verfaillie CM. p210^{BCR/ABL}-Induced Alteration of pre-mRNA Splicing in Primary Human CD34⁺ Hematopoietic Progenitor Cells. *Leukemia* 18:727-33, 2004. (IF: 7.5)
112. Dylla S, Deyle D, Theunissen K, Verfaillie CM. Integrin engagement-induced inhibition of human myelopoiesis is mediated by proline-rich tyrosine kinase 2 gene products. *Exp Hematol* 32:365-74, 2004. (IF: 3.1)
113. Wang X, Galegos G, Carsten Rickers R, Swingen C, O'Brien T, Wilke N, Vazquez G, Verfaillie CM, Osman N, Jerosch-Herold M, Bolman III M. Tagged MR Applications of magnetic resonance imaging for cardiac stem cell therapy. *J Interv Cardiol* 17:37-46, 2004. (IF: 1.2)
114. Lakshmipathy U, Pelacho B, Sudo K, Coucouvanis E, Verfaillie CM. Efficient Transfection of Embryonic and Adult Stem Cells. *Stem Cells* 22:531-43, 2004. (IF: 7.5)
115. Rickers C, Gallegos R, Seethamraju RT, Wang X, Swingen C, Jayaswal A, Rahrmann EP, Kastenber ZJ, Clarkson CE, Bianco R, O'Brian T, Verfaillie CM, Bolman RM 3rd, Wilke N, Jerosch-Herold M. Applications of magnetic resonance imaging for cardiac stem cell therapy. *J Interv Cardiol*. 17:37-46, 2004. (IF: 1.2)
116. Melikova S, Dylla S, Verfaillie CM. Role of phosphatidylinositol 3-kinase and proline-rich tyrosine kinase 2 in beta1-integrin signaling in normal hematopoiesis. *Exp Hematol*. 32:1051-6, 2004. (IF: 3.1)
117. Leung AYH, Mandenhall EM, Kwan TTF, Liang R, Eckfeldt C, Chen E, Matthias Hammerschmidt M, Grindle S, Ekker SE, Verfaillie CM. Characterization of expanded intermediate cell mass in zebrafish chordin morphant. *Dev Biol* 277:235-54, 2005. (IF: 4.7)
118. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Brown CA, Krepski TP, McGlave PB, Miller JS, Verfaillie CM, Wagner JE. Transplantation of two unrelated donor umbilical cord blood units in adults with hematologic malignancy: impact on engraftment, chimerism and GVHD. *Blood* 105:1343-7, 2005. (IF: 10.9)
119. Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, Holt IE, Eckfeldt CE, Schmidt SY, von Kalle C, Persons DA, Billings E, Verfaillie CM, Nienhuis AW, Wolsberg TG, Dunbar CE, Calmels B. Distinct retroviral and lentiviral vector integration patterns in the genome of nonhuman primate long-term repopulating hematopoietic stem and progenitor cells. *PLoS Biol*. 2:e423, 2004. (IF: 13.5)
120. Theunissen K, Verfaillie CM. A multifactorial analysis of umbilical cord blood, adult bone marrow and mobilized peripheral blood progenitors using the improved ML-IC assay. *Exp Hematol* 33:165-72, 2005. (IF: 3.1)
121. Leung AYH, Ali N, Glissan M, Verfaillie CM. *All-Trans* Retinoic Acid (ATRA) enhances maintenance of primitive human hematopoietic progenitors and skews them towards myeloid differentiation in a stroma non-contact culture system. *Exp Hematol* 33:422-7, 2005. (IF: 3.1)
122. Jongen-Lavrencic M, Salesse S, Delwel R, Verfaillie CM. BCR/ABL-mediated down regulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells. *Leukemia* 19:373-80, 2005. (IF: 6.9)
123. Lakshmipathy U, Verfaillie CM. Stem cell plasticity. *Blood Rev*. 19:29-38, 2005 (IF: 4.2)
124. Tolar J, Osborn M., Bell S, McElmurry R, Xia L, Riddle M, Panoskaltis-Mortari A, Jiang Y, McIvor RS, Contag CH, Yant SR, Kay MA, Verfaillie CM, Blazar BR.¹ Real time in vivo imaging of stem cells following transgenesis by transposition. *Mol Ther* 12:42-8, 2005. (IF: 5.8)
125. Nahmias Y, Schwartz RE, Verfaillie CM, Odde DJ. Laser-guided direct writing for three-dimensional tissue engineering. *Biotechnol Bioeng*. 92:129-36, 2005 (IF: 3.1)

126. Eckfeldt CE, Mendenhall EM, Pickart MA, Grindle S, Ekker SE, [Verfaillie CM](#). Functional analysis of human hematopoietic stem cell gene expression using zebrafish. *PLoS Biology*, 2005 Jul; [Epub ahead of print] (IF: 13.5)
127. Schwartz RE, Linehan JL, Painschab MS, Hu WS, [Verfaillie CM](#), Kaufman DS. Defined conditions for development of functional hepatic cells from human-embryonic stem cells. *Stem Cells Dev* 14:643-55, 2005 (IF: 3.2)
128. Nahmias Y, Schwartz RE, Hu WS, [Verfaillie CM](#), Odde DJ. Endothelium-mediated hepatocyte recruitment in the establishment of liver-like tissue *in vitro*. *J Bioeng* 12:1627-38, 2006. (IF: 3.9)
129. Tolar J, O'Shaughnessy MJ, Panoskaltis Mortari A, McElmurry RT, Bell S, Riddle M, McIvor RS, Yant SR, Kay MA, Krause D, [Verfaillie CM](#), Blazar BR1. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. *Blood* 107:4182-8, 2006 (IF: 10.9)
130. Leung A, Ekker S, [Verfaillie CM](#). Natural regression of primitive hematopoiesis in zebrafish embryos is mediated by the death receptor gene. *Exp Hematol* 34:27-34, 2006 (IF: 3.1)
131. Burns TC, Ortiz-González XR, Gutiérrez Pérez M, Keene CD, Sharda R, Demorest ZL, Jiang Y, Soriano M, Nakagawa Y, M. Rosario Luquin Piudo MR, Garcia-Verdugo JM, Prósper F, Low WL, [Verfaillie CM](#). Thymidine analogues are transferred from donor to host cells in the central nervous system. *Stem Cells* 24:1121-7 2006 (IF: 7.5)
132. Maes C, Coenegrachts L, Daci E, Stockmans I, Luttun A, Petryk A, Gopalakrishnan R, Moermans K, Smets N, [Verfaillie CM](#), Carmeliet P, Bouillon R, Carmeliet G. Placental growth factor is essential for mesenchymal cell development, cartilage turnover and bone remodeling during fracture repair, *J Clin Invest*. 116:1230-42, 2006. (IF: 16.9)
133. Nahmias Y, Schwartz RE, Hu WS, [Verfaillie CM](#), Odde DJ. Endothelium-mediated hepatocyte recruitment in the establishment of liver-like tissue *in vitro*. *Tissue Eng*. 12:1627-38, 2006. (IF: 4.4)
134. Zeng L, Rarhman E, Zhang J, [Verfaillie CM](#). Isolation and characterization of multipotent adult progenitor cells from swine bone marrow. *Stem Cells* 24:2355-66, 2006. Epub 2006 Aug 24 (IF: 7.5)
135. Snykers S, Vanhaecke T, Papeleu P, Luttun A, Jiang Y, [Verfaillie CM](#), Rogiers V. Sequential exposure to cytokines reflecting embryogenesis: the key for *in vitro* differentiation of adult bone marrow stem cells into functional hepatocyte-like cells. *Toxicol Sci*. 94:330-41, 2006. (IF: 3.1)
136. Gupta S, [Verfaillie CM](#), Aronow BJ, Chmielewski D, Kren S, Solis S, Eidman K, Connaire J, Lakshmiapati U, Heremans Y, Lund T, Lenvik T, Blackstad M, Jiang Y Luttun A, Rosenberg ME. Isolation, Characterization, and Therapeutic Delivery of Kidney Derived Stem Cells. *J Am Soc. Nephrology* 17:3028-40, 2006. (IF: 7.1)
137. Ross JJ, Hong Z, Keirstead SA, Zeng L, Willenbring B, Isenberg B, Lee E-H, Reyes M, Weir EK, Tranquillo RT, [Verfaillie CM](#). Cytokine Specific Induction of Smooth Muscle Phenotype and Function in Multipotent Adult Progenitor Cells. *J Clin Invest*. 116:3139-49 (IF: 16.9)
138. Chase LG, Ulloa-Montoya F, Heremans Y, Kidder BL, [Verfaillie CM](#). Islet-Derived Fibroblast-like Cells are not Derived via Endoderm-Mesoderm Transition from Pdx-1 or Insulin Positive Cells. *Rapid Communication, Diabetes* 56:3-7, 2007 (IF: 8)
139. Aranguren X, Clavel C, Luttun A, Barajas MA, Moreno C, Abizanda G, Echavarri A, Araña M, Soriano M, Andreu EJ, Merino J, Garcia-Verdugo JM, [Verfaillie CM](#), Prósper F. *In vitro* and *in vivo* arterio-venous specification from human multipotent adult progenitor cells. *Blood* 109:2634-42, 2007. (IF: 10.9)
140. Patterson L, Eckfeldt CE, Mendenhall EM, [Verfaillie CM](#), Ekker SE, Patient R. The transcription factors, *Scf* and *Lmo2*, act together during development of the hemangioblast in zebrafish. *Blood* 109:2389-98, 2007 (IF: 10.9)
141. Pickart MA, Klee EW, Nielson AL, Sivasubbu S, Mendenhall EM, Bill RB, Chen E, Eckfeldt CE, Knowlton M, Robu ME, Larson JD, Deng Y, Schimmenti LA, Ellis BM, [Verfaillie CM](#), Hammerschmidt M, Farber SA, Ekker SC. Genome-wide reverse genetics framework to identify novel functions of the vertebrate secretome. *PLoS ONE*. 2006 Dec 20;1:e104.
142. Serafini M, Dylla SJ, Oki M, Heremans Y, Buckley S, Jiang Y, Bryder D, Rossi DJ, Panoskaltis-Mortari A, O'Shaughnessy MS, Nelson-Holte M, Weissman IL, Blazar BR, [Verfaillie CM](#). Complete Lymphohematopoietic Reconstitution by Multipotent Adult Progenitor Cells. *J Exp Med* 204:129-39. (IF: 15.6)
143. Cheung AM, Tam CK, Chow HC, [Verfaillie CM](#), Liang R, Leung AY. All-trans retinoic acid induces proliferation of an irradiated stem cell supporting stromal cell line AFT024. *Exp Hematol*. 35:56-63, 2007 (IF: 3.1)
144. Pelacho B, Asakura J, Luttun B, Ross J, Heremans Y, Nelson-Holte MH, Zhang J, Jiang Y, [Verfaillie CM](#). Functional improvement following transplantation of Multipotent Adult Progenitor Cells in a mouse model of acute myocardial infarction is due to trophic factors. *J Tissue Eng Regen Med*. 1:51-9, 2007. (no IF yet)
145. Zeng L, Hu Q, Wang X, Mansoor A, Lee J, Feygin J, Zhang G, Suntharalingam P, Boozer S, Mhashilkar A, Panetta CJ, Swingen C, Deans R, From AH, Bache RJ, [Verfaillie CM](#), Zhang J. Bioenergetic and Bioenergetic and Functional Consequences of Bone Marrow-Derived Multipotent Progenitor Cell Transplantation in Hearts With Postinfarction Left Ventricular Remodeling. *Circulation* 115 1866-75, 2007 (IF: 12.8)
146. Dao MA, Creer MH, Nolta JA, [Verfaillie CM](#). Biology of umbilical cord blood progenitors in bone marrow niches. *Blood* 110:74-81. 2007 (IF: 10.9)
147. Ma ACH, Chan P-K, Leung JC, Chan LYY, Meng A, [Verfaillie CM](#), Liang R, Leung AYH and Rachel Lin R. The role of survivin in angiogenesis during zebrafish embryonic development. *BMC Dev Biol* 7:50, 2007 (IF: 3.3)

148. Ulloa-Montoya F, Kidder BL, Pauwelyn K, Chase L, Luttun A, Crabbe A, Geeraerts M, Sharov AA, Piao Y, Ko MSH, Hu WS, Verfaillie CM Unique molecular signature of multipotent adult progenitor cells. *Genome Biol.* 2007 Aug 6;8(8):R163 (IF: 6.6)
149. Liu Z, Jiang Y, Hao H, Gupta K, Xu J, Chu L, McFalls EO, Zweier JL, Verfaillie CM, Bache RJ. Endothelial Nitric Oxide Synthase Is Dynamically Expressed during Bone Marrow Stem Cell Differentiation into Endothelial Cells. *Am J Physiol Heart Circ Physiol.* 293:H1760-5, 2007. (IF: 4.2)
150. Meers S, Kasran A, Boon L, Lemmens J, Ravoet C, Boogaerts M, Verhoef G, Verfaillie C, Delforge M. Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40 CD40L interactions with T helper cells. *Leukemia.* 21:2411-9, 2007 (IF: 6.9)
151. Hajdu M, Luttun A, Pelacho B, Burns TC, Chase L, Gutiérrez-Pérez M, Jiang Y, Lenvik T, Vas V, Uher F, Sebestyén A, Verfaillie C. Transcriptional characterization of the notch signaling pathway in rodent multipotent adult progenitor cells. *Pathol Oncol Res.* 13:302-10, 2007 (no IF yet)
152. Sahin MB, Schwartz RE, Buckley SM, Heremans Y, Chase L, Hu W-S, Verfaillie CM. Isolation and characterization of a novel population of progenitor cells derived from unmanipulated rat liver. *Liver Transpl.* 14:333-345, 2008 (IF: 3.7)
153. Aranguren X, McCue JD, Xiao-Hong Zhu X-H, Yi Zhang Y, Zhang X, Schroeder BS, Harris N, Pelacho B, Nelson-Holte MH, Hall JL, Chen W, Verfaillie CM, Luttun A. Undifferentiated Multipotent Adult Progenitor Cells functionally improve hind limbs after femoral artery ligation in mice. *J Clin Invest.* 118:505-514, 2008. (IF: 16.9)
154. Xu J, Liu X, Jiang Y, Chu L, Hao H, Liu Z, Verfaillie C, Zweier J, Gupta K, Liu Z. MAPK/ERK signaling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell. *J Cell Mol Med.* 12:2395-406, 2008. (IF: 6.8)
155. Kidder B, Hirsch B, Verfaillie CM, Coucouvanis E: Embryonic stem cells contribute to chimera without evidence of cell fusion. *Cloning Stem Cells* 10:231-48, 2008 (IF: 2.9)
156. Chu L, Jiang Y, Hao H, Xia Y, Xu J, Liu Z, Verfaillie CM, Zweier JL, Liu Z. Nitric oxide enhances Oct-4 expression in bone marrow stem cells and promotes endothelial differentiation. *Eur J Pharmacol.* 591:59-65, 2008. (IF: 2.4)
157. Liu Z, Lei M, Jiang Y, Hao H, Chu L, Xu J, Luo M, Verfaillie CM, Zweier JL, Liu Z. High glucose attenuates VEGF expression in rat multipotent adult progenitor cells in association with inhibition of JAK2/STAT3 signaling. *J Cell Mol Med.* 2009. (IF: 6.8)
158. Tjwa M, Moua R, Moons L, Plaisance S, de Mol M, Jansen S, Dewerchin M, Verfaillie C, Carmeliet, P. Fibrinolysis-independent role of plasmin and its activators in the hematopoietic recovery after myeloablation. *J Cell Mol Biol* 2009 (IF: 6.8)
159. Lin Y, Ling Feng L, Hamajima Y, Komori M, Terry Burns T, Wang D, Verfaillie CM, Anderson J, Low WC. Directed Differentiation of Mouse Cochlear Neural Progenitors in vitro *Am J Physiology* 2009 (IF: 6.8)
160. Tjwa M, Sidenius N, Moura R, Jansen S, Theunissen K, Andolfo A, De Mol M, Dewerchin M, Moons L, Blasi F, Verfaillie C, Peter Carmeliet P. Membrane-anchored UPAR regulates the quiescence, maintenance, engraftment and mobilization of hematopoietic progenitors. *J Clin Invest*, 119:1008-18 2009 (IF: 16.9)
161. Tjwa M, Moons L, Verfaillie C, Carmeliet P. Antibiotics may impair hematopoietic recovery after cytotoxic myeloablation. *Blood* 113:1608-9, 2009 (IF: 10.9)

Reviews, commentaries

162. McGlave P, Verfaillie C, Miller J. Chronic myelogenous leukemia: in search of the benign hematopoietic stem cell. *Stem Cells* 11 S 3: 10-3, 1993 (IF: 7.5)
163. Verfaillie CM, Hurley R, Bhatia R, McCarthy JB. Role of bone marrow matrix in normal and abnormal hematopoiesis. *Crit Rev Oncology/Hematology* 16: 201-224, 1994. (IF: 4.6)
164. Verfaillie CM. Can we culture human stem cells ex vivo: Concise Review. *Stem Cells* 12: 466-467, 1994. (IF: 7.5)
165. Miller JS, Verfaillie C, McGlave P. Expansion and activation of human natural killer cells for autologous therapy. *J Hematotherapy* 3: 71-74. 1994. (IF: 2.6)
166. Miller JS, Verfaillie C, McGlave P. Expansion and activation of human natural killer cells as therapy for autologous transplantation. *Progress in Clinical & Biol Res* 389: 39-45, 1994. (IF: 2.31)
167. Bhatia R, Verfaillie CM. Autografting for CML (Review). *Curr Opin Hematol* 2:436-443, 1995. (IF: 4.5)
168. Verfaillie CM. Chemokines as inhibitors of hematopoietic progenitor. *J Lab Clin Med* 127: 148-150, 1996 (Editorial). (IF: 1.8)
169. McGlave PB, Bhatia R, Verfaillie CM. Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML. *Bone Marrow Transplant* 17 (suppl.3) S65-S66, 1996. (IF: 2.6)
170. Verfaillie CM. CML and stem cells (Review). *Hem & Onc Clin of N Amer* 11:1079-114, 1997
171. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myelogenous leukemia (Review). *Blood* 89: 2623-2634, 1997. (IF: 10.9)
172. Verfaillie CM, Hurley R, Lundell BI, Bhatia R. Integrin-mediated regulation of hematopoiesis: Do BCR/ABL induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? (Review). *Acta Haematologica* 97: 40-52, 1997. (IF: 1.22)
173. Verfaillie CM, Hurley R, Lundell B, Zhao R, Prosper F, Delforge M, Bhatia R. Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? *J Lab Clin Med* 129:584-591, 1997. (IF: 1.8)

174. Bhatia R, Verfaillie CM. The effect of interferon-alpha on $\beta 1$ -integrin mediated adhesion and growth regulation in chronic myelogenous leukemia (Review). *Leuk Lymphoma* 28: 241-254, 1998
175. Verfaillie CM, Gupta P, Prosper F, Hurley R, Lundell B, Bhatia R. Stromal extracellular matrix components as growth regulators for human hematopoietic progenitors (Review). *Contemporary Oncology (Poznan, Poland)* 4: 167-175, 1998
176. Verfaillie CM, Prosper P, Liu JH, Weber E, Zhao RCH, Bhatia R. Role of integrins in hematopoiesis (Review). *Hematologia, Citocinas, Immunoterapia Y Terapia Celular (Barcelona, Spain)* 1: 314-126, 1998
177. Verfaillie CM. Chronic Myelogenous Leukemia: Too much or too little growth, or both? *Leukemia* 12: 136-138, 1998. (Editorial) (IF: 6.9)
178. Verfaillie CM. Adhesion receptors as regulators of the hematopoietic process. *Blood*. 92: 2609-2612, 1998. (IF: 10.9)
179. Verfaillie CM, Gupta P, Prosper F, Hurley R, Lundell B, Bhatia R. The Hematopoietic Microenvironment: Stromal Extracellular Matrix Components As Growth Regulators For Human Hematopoietic Progenitors (Review). *Hematol* 4: 321-3, 1999
180. Verfaillie CM: Chronic Myelogenous Leukemia: from pathogenesis to therapy (Review). *J. Hematotherapy* 81:3-13, 1999. (IF: 2.6)
181. Verfaillie CM, Mclvor RS, Zhao RCH: Gene therapy approaches for CML and ALL. *Molecular Medicine Today*, 5:359-66, 1999. (IF: 3.5)
182. Verfaillie CM, Ploemacher R, Di Persio J, Sutherland R, Serke S, Johnsen HE, Noga S, Negrin R. Assays to determine hematopoietic stem cell content in blood or marrow grafts. *Cytotherapy* 1: 41-49, 1999. (IF: 1.39)
183. Verfaillie CM. Meeting report on an NHLBI workshop on *ex vivo* expansion of stem cells, July 29, 1999, Washington D.C. *Exp Hematol*.28:361-4, 2000. (IF: 3.1)
184. Prosper F, Verfaillie CM. Regulation of hematopoiesis through adhesion receptors (Review). *J. Leukocyte Biol*. 69:307-16, 2001. (IF: 4.2)
185. Verfaillie CM. Stem cell plasticity (Review). *Graft* 3:296-300, 2001
186. Reyes M, Verfaillie CM. Characterization of Multipotent Adult Progenitor Cells, a subpopulation of mesenchymal stem cells. *NY Acad Science* 938:231-3; discussion 233-5, 2001 (IF: 1.78)
187. Verfaillie CM. Hematopoietic stem cells for transplantation (Review). *Nat Immunol* 3:314-317, 2002. (IF: 27.0)
188. Verfaillie CM. Optimizing Hematopoietic stem cell engraftment: a novel role for thrombopoietin. *J Clin Invest*. 110, 303-4, 2002 (commentary) (IF: 16.9)
189. Verfaillie CM. Adult stem cells: A case for pluripotency? (Review). *Trends Cell Biol* 12:502-8, 2002. (IF: 14.3)
190. Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression (Review). *Leukemia* 16:1402-11, 2002. (IF: 6.9)
191. Salesse S, Verfaillie CM. Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML (Review). *Oncogene* 21:8605-11, 2002. (IF: 6.8)
192. Salesse S, Verfaillie CM. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia (Review). *Oncogene* 21:8547-59, 2002. (IF: 6.8)
193. Verfaillie CM, Pera MF, Lansdorp PM. Stem cells: hype and reality (Review). *Blood (Am Soc Hematol Educ Program)* 369-91, 2002. (IF: 10.1)
194. Verfaillie CM, Schwartz R, Reyes M, Jiang Y. Unexpected potential of adult stem cells (Review). Prosper F, Verfaillie CM. *Adult stem cells An Sist Sanit Navar*. 26:345-56, 2003 (Spanish)
195. Verfaillie CM. Stem cell research: state of the art. *Belg Tijdschrift voor Geneeskunde*. 65:291-2, 2003 (Dutch)
196. Wagner JE, Verfaillie CM. Ex vivo expansion of umbilical cord blood hemopoietic stem and progenitor cells. *Exp Hematol*. 32:412-3, 2003. (IF: 3.1)
197. Wagner JE, Verfaillie CM. cGMP manufacture of the multipotent adult progenitor cell (MAPC) and strategy for clinical testing. *Biol Blood Marrow Transplant* 10:73, 2004. (IF: 3.27)
198. Ortiz-Gonzalez XR, Keene CD, Verfaillie CM, Low WC. Neural induction of adult bone marrow and umbilical cord stem cells. *Curr Neurovasc Res* 1:207-13, 2004. (IF: 1.4)
199. Lakshminpathy U, Verfaillie CM. Stem cell plasticity. *Blood Rev*. 19:29-38, 2005 (IF: 4.16)
200. Eckfeldt CE, Mendenhall EM, Verfaillie CM. The molecular repertoire of the almighty stem cell. *Nat Rev Mol Cell Biol*. 6:726-37, 2005 (IF: 29.8)
201. Jahagirdar BN, Verfaillie CM. Multipotent adult progenitor cell and stem cell plasticity. *Stem Cell Rev*. 1: 53-9, 2005. (IF: 1.5)
202. Ulloa-Montoya F, Seth G, Verfaillie CM, Hu W-S. Stem cell culture engineering. *J Biosci Bioeng*. 100:12-27, 2005. (IF: 0.9)
203. Pauwelyn KA, Verfaillie CM. Transplantation of undifferentiated, bone marrow-derived stem cells. *Curr Top Dev Biol*. 74:201-51, 2006. (IF: 4.6)
204. Verfaillie CM. Stem cell research: future implications for internal medicine. *Acta Clin Belg*. 60:277-83, 2005. (IF: 0.58)
205. Luttun A, Ross JJ, Aranguren XL, Prosper F, Verfaillie CM. Differentiation of multipotent adult progenitor cells to functional endothelial and smooth muscle cells. *Curr Protoc Immunol*. Dec;Chapter 22:Unit 22F.9, 2006.
206. Serafini M, Verfaillie CM. Pluripotency in adult stem cells: state of the art. *Semin Reprod Med*. 24:379-88, 2006.

207. Luttun A, Verfaillie CM. A perspective on stem cells as a tool for in vitro testing. *ALTEX*. 2006;23 Suppl:388-92.
208. Verfaillie CM. Introduction to Methods/Techniques paper section of Experimental Hematology. *Exp Hematol*. 34:1588, 2006 (IF: 3.5)
209. Ross JJ, Verfaillie CM. Neural plasticity of adult stem cells: Fact of fiction? *Philos Trans R Soc Lond B Biol Sci*. 2008 Jan 29;363(1489):199-205. (IF: 5.5)
210. Pelacho B, Aranguren XL, Mazo M, Abizanda G, Gavira JJ, Clavel C, Gutierrez-Perez M, Luttun A, Verfaillie CM, Prosper F. Plasticity and cardiovascular applications of multipotent adult progenitor cells. *Nat Clin Pract Cardiovasc Med*. 4 Suppl 1:S15-20, 2007 (IF: 4.7)
211. Clavel C, Verfaillie CM. Bone-marrow-derived cells and heart repair. *Curr Opin Organ Transplant* 13(:36-43; 2008
212. Lakshmipathy U, Buckley S, Verfaillie C. Gene transfer via nucleofection into adult and embryonic stem cells. *Methods Mol Biol*. 407:115-26, 2007
213. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. *Exp Cell Res*. 314:1937-44, 2008. (IF: 3.9)
214. Verfaillie CM. Bony endothelium: tumor-mediated transdifferentiation? *Cancer Cell*. 14:193-4, 2008. (IF: 23.9)
215. Aranguren XL, Verfaillie CM, Luttun A. Emerging hurdles in stem cell therapy for peripheral vascular disease. *J Mol Med*. 2008 [Epub ahead of print]. (IF: 5.9)
216. Verfaillie C. The undoing of differentiation by four defined factors: A big step forward towards generating patient specific pluripotent stem cells. *J Hepatol*. 2008. [Epub ahead of print] (IF: 6.6)
217. Sancho-Bru P, Najimi M, Caruso M, Pauwelyn K, Cantz T, Forbes S, Roskams T, Ott M, Gehling U, Sokal E, Verfaillie CM, Muraca M. Stem and progenitor cells for liver repopulation: can we standardize the process from bench to bedside? *Gut* 2008 (In Press) (IF 10.1)
218. Adjaye JA, Byskov AG, Cibelli JB, De Maria R, Minger S, Sampaolesi M, Testa G, Verfaillie C, Zernicka-Goetz M, Schöler H, Boiani M, Crosetto N, Redi CA. Pluripotency and differentiation in embryos and stem cells. *Int J Dev Biol*. 2008;52(7):801-9. (IF 2.8)

Book Chapters

1. Verfaillie CM. Intensive therapy of chronic myelogenous leukemia. In *High dose Cancer Therapy*. Eds. JO Armitage, KH Antman, Williams and Wilkins, 1995.
2. Verfaillie CM, Gupta P, Bhatia R. Stromal extracellular matrix components as growth regulators for human hematopoietic progenitors. In Press.
3. Verfaillie CM, Bhatia R, McGlave PB. Autografting in chronic myeloid leukemia. In: "Hematopoietic Cell Transplantation". Eds. Thomas, Blume, Forman. Blackwell Publishers. 2nd Edition, Chapter 88, p990-1003
4. Verfaillie CM. Anatomy and Physiology of Hematopoiesis. In "Hematology: Basic Principles and Practice". Eds. Hoffman, Benz, Shattil, Furie, Cohen, Silberstein and McGlave. Churchill Livingstone Press, 1998.
5. Verfaillie CM, Prosper F, Liu Y, Zhao RCH, Bhatia R. Cell-Signaling By Adhesion Receptors In Normal And Leukemic Hematopoiesis. Eds. AD Ho and RE Champlin, Cambridge University Press.
6. Verfaillie CM. Ex vivo expansion of hematopoietic stem cells. In "Hematopoiesis: a developmental approach". In Hematopoiesis, a developmental approach. p. 119-130, 2001. Ed. L. Zon. Oxford University.
7. Verfaillie CM, Zhao RCH. Gene therapy for chronic myelogenous leukemia. In *Gene therapy for Cancer*, p 331-337, 2002. Eds Lattimer and EC and Gerson SL. Academic press
8. Prosper F, Verfaillie CM. Human Pluripotent stem cells from bone marrow. In *Human Embryonic stem Cells*, pp.89-113, Editors Chiu AY and Rao MS, Humana Press, 2003
9. Brunstein C, Dylla S, Verfaillie CM. Chromosomal translocations in hematological malignancies. In 2003
10. Brunstein C, Verfaillie CM. The Bone Marrow Microenvironment. In: "Hematopoietic Cell Transplantation". Eds. Thomas, Blume, Forman. Blackwell Publishers. 3rd Edition, 2004.
11. Schwartz R, Verfaillie CM. Multipotent adult stem cells. In "Human Embryonic Stem Cells". 2003
12. Monique Dao, Verfaillie CM. Anatomy and Physiology of Hematopoiesis. in "Hematology: Basic Principles and Practice". Eds. Hoffman, Benz, Shattil, Furie, Cohen, Silberstein and McGlave. Churchill Livingstone Press, 2004.
13. Leung AY, Verfaillie CM. Stem Cell Model of Hematopoiesis. in "Hematology: Basic Principles and Practice". Eds. Hoffman, Benz, Shattil, Furie, Cohen, Silberstein and McGlave. Churchill Livingstone Press, 2004.
14. Tzanakakis M, Verfaillie CM. Advances in Stem cell Culture Systems. Marcel Decker Publishers, 2003
15. Adassi A, Verfaillie CM. Multipotent adult progenitor cells. In "Handbook of stem cells". 2004
16. Verfaillie CM. "Adult" stem cells: tissue specific or not? In "Handbook of stem cells". 2004

Editor / Guest Editor

1. Eds. McGlave PB and Verfaillie CM. Biology and Therapy of Chronic Myelogenous Leukemia. *Hem & Onc Clin of N Amer* 12: 1-207, 1998
2. Eds Low W and Verfaillie CM: Stem Cells And Regenerative Medicine, 2008

Sequential Exposure to Cytokines Reflecting Embryogenesis: The Key for *in vitro* Differentiation of Adult Bone Marrow Stem Cells into Functional Hepatocyte-like Cells

Sarah Snykers,^{*,1} Tamara Vanhaecke,* Peggy Papeleu,* Aernout Lutun,† Yuehua Jiang,†
Yvan Vander Heyden,‡ Catherine Verfaillie,† and Vera Rogiers*

^{*}Department of Toxicology, Vrije Universiteit Brussel (VUB), B-1090 Brussels, Belgium; [†]Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota 55455; and [‡]Department of Analytical Chemistry, VUB, B-1090 Brussels, Belgium

Received May 19, 2006; accepted July 5, 2006

Differentiation of adult bone marrow stem cells (BMSC) into hepatocyte-like cells is commonly performed by continuous exposure to a cytokines-cocktail. Here, it is shown that the differentiation efficacy *in vitro* can be considerably enhanced by sequential addition of liver-specific factors (fibroblast growth factor-4, hepatocyte growth factor, insulin-transferrin-sodium selenite, and dexamethasone) in a time-dependent order that closely resembles the secretion pattern during *in vivo* liver embryogenesis. Quantitative RT-PCR analysis and immunocytochemistry showed that, upon sequential exposure to liver-specific factors, different stages of hepatocyte differentiation, as seen during liver embryogenesis, can be mimicked. Indeed, expression of the early hepatocyte markers alpha-fetoprotein and hepatocyte nuclear factor (HNF)3 β decreased as differentiation progressed, whereas levels of the late liver-specific markers albumin (ALB), cytokeratin (CK)18, and HNF1 α were gradually upregulated. In contrast, cocktail treatment did not significantly alter the expression pattern of the hepatic markers. Moreover, sequentially exposed cells featured highly differentiated hepatic functions, including ALB secretion, glycogen storage, urea production, and inducible cytochrome P450-dependent activity, far more efficiently compared to the cocktail condition. In conclusion, sequential induction of the differentiation process, analogous to *in vivo* liver development, is crucial for *in vitro* differentiation of adult rat BMSC into functional hepatocyte-like cells. This model may not only be applicable for *in vitro* studies of endoderm differentiation but it also provides a “virtually unlimited” source of functional hepatocytes, suitable for preclinical pharmacological research and testing, and cell and organ development.

Key Words: bone marrow stem cells; hepatocytes; sequential differentiation; liver-specific growth factors; liver embryonic development; *in vitro*.

INTRODUCTION

Drug development is aimed at identifying pharmacologically active drug candidates with a favorable toxicologic profile. The increasing number of safety criteria, imposed on newly designed molecules, leads nowadays to the urgent need of *in vitro* techniques in the industry, developed according to the principle of Russell and Burch. To date, several hepatocyte-based *in vitro* models are available, however, they are not yet accepted into regulations, as they still require better characterization and optimization to reach the validation stage. Most primary hepatocyte cultures are in fact hampered by progressive occurrence of differentiation (De Smet *et al.*, 2001; LeCluyse *et al.*, 1996; Rogiers and Vercruysse, 1993). An alternative approach would be the use of postnatal progenitor/stem cells.

Indeed, until recently, it was believed that tissue-specific stem cells could only differentiate into cells of the tissue of origin. However, a number of recent studies have suggested that adult stem cells may overcome germ lineage restrictions and express molecular characteristics of cells of different tissue origin, which has been termed “plasticity” (Jackson *et al.*, 2001; Krause *et al.*, 2001; Theise *et al.*, 2000; Vourc’h *et al.*, 2004). For example, hematopoietic cells may acquire characteristics of cardiomyocytes, cells of lung, gut, liver, blood vessels, skin, etc. (Jackson *et al.*, 2001; Krause *et al.*, 2001; Theise *et al.*, 2000). This apparent plasticity can at least in some instances be explained by cell fusion (Wang *et al.*, 2003). Other studies have described nonhematopoietic stem cells from bone marrow that are capable of differentiating *in vitro* in cells with mesodermal, ectodermal, and endodermal features (Jiang *et al.*, 2002; Reyes *et al.*, 2001; Yoon *et al.*, 2005). The mechanism through which these cells gain multipotency is not totally understood (Verfaillie, 2000). Multipotent adult progenitor cells, for instance, can be induced to express phenotypic and functional characteristics of hepatocytes; however, the degree of differentiation obtained till now is incomplete (Schwartz *et al.*, 2002).

Therefore, in order to develop an *in vitro* model suitable for pharmaco-toxicological purposes, attempts were made here to

¹ To whom correspondence should be addressed at Department of Toxicology, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium. Fax: +32 2 477 45 82. E-mail: sarah.snykers@vub.ac.be.

optimize the differentiation efficiency of nonhematopoietic stem cells from bone marrow into functional hepatocytes.

Liver development is accomplished by a sequential array of biological events. Each step of cell growth and differentiation is tightly regulated by cell autonomous mechanisms and extracellular signals, including cytokines and growth factors. More specifically, during the initial phase of murine liver ontogeny (embryonic days [E] 8–9), fibroblast growth factors (FGFs), derived from adjacent cardiac mesoderm, commend the foregut endoderm to form the liver primordium (Duncan, 2000; Jung *et al.*, 1999). During and after the mid-stage of hepatogenesis, surrounding mesenchymal cells secrete hepatocyte growth factor (HGF) and support as such the fetal hepatocytes (Kinoshita and Miyajima, 2002; Zaret, 2002). Around E11, the fetal liver becomes the major site for hematopoiesis. During this stage, hematopoietic stem cells produce oncostatin M that, in the presence of glucocorticoids, not only promotes fetal hepatic cell differentiation and maturation but also suppresses embryonic hematopoiesis. In contrast, oncostatin M alone fails to induce differentiated liver phenotypes, implying that glucocorticoids are essential triggers for hepatic maturation (Kinoshita and Miyajima, 2002; Schmidt *et al.*, 1995; Zaret, 2002). In rodents, the final step of hepatic differentiation takes place several days after birth. The lack of terminal differentiation of primary hepatocytes in culture evidences that additional signals, probably generated through the extracellular matrix, are necessary (Kinoshita and Miyajima, 2002).

Here, the liver development was taken as exemplar to establish a culture model that more readily supports robust differentiation of bone marrow stem cells (BMSC) to mature hepatocyte-like cells. We compared two experimental setups: (1) BMSC were treated with a cocktail of liver-specific factors (FGF-4, HGF, insulin-transferrin-sodium selenite [ITS], and dexamethasone [Dex]) as previously described (Schwartz *et al.*, 2002) or (2) innovative in this field, BMSC were exposed to a sequence of these compounds in a manner that closely reflects their temporal expression during *in vivo* hepatogenesis (FGF-4, followed by HGF, followed by a combination of HGF, ITS, and Dex).

MATERIALS AND METHODS

Isolation and culture of undifferentiated rat BMSC. BMSC were isolated from male Fisher rats (4–6 weeks old) and cultured as described by Jiang *et al.* (2002). Labware used for expansion of BMSC included Corning 75 and 150 cm² tissue culture flasks, polystyrene (both from VWR, Leuven, Belgium). Cell karyotyping, neuroectodermal, and endothelial differentiation were determined as previously described (Jiang *et al.*, 2002, 2003; Reyes *et al.*, 2001). Rats had access to food and water *ad libitum* and were housed according to guidelines from the Institutional Animal Care and Use Committee of the University of Minnesota.


Hepatocyte differentiation. Rat BMSC from 60 population doublings on were used for differentiation into hepatocyte-like cells. BMSC were plated at 21×10^3 cells/cm² on 1 mg/ml collagen type I-coated culture plates and dishes (BD Falcon 24-well plate, polystyrene; BD Falcon 35 × 10 mm petri dishes,

polystyrene; NUNC F96 microwell plate, black, polystyrene; NUNC F96 microwell plate, clear, polystyrene [all from VWR]) in low-serum expansion medium (Jiang *et al.*, 2002; Reyes *et al.*, 2001). Once cells reached 100% confluence, they were washed with basal medium (Jiang *et al.*, 2003) supplemented with 0.03mM nicotinamide, 0.25mM sodium-pyruvate and 1.623mM glutamine (all from Sigma, Bornem, Belgium). Subsequently, cells were cultured in the presence of liver-specific cytokines and growth factors, added either as a cocktail (basal medium + 10 ng/ml FGF-4, 20 ng/ml HGF [all from R&D Systems, Minneapolis, MN], 1×10^{-8} ITS and 20 μ g/l Dex [all from Sigma]) or sequentially (days 0–3: basal medium + 10 ng/ml FGF-4; days 3–6: basal medium + 20 ng/ml HGF; from day 6 on: basal medium + 20 ng/ml HGF + 1×10^{-8} ITS and 20 μ g/l Dex). Differentiation media were changed every 3 days. A schematic presentation of the differentiation procedure is shown in Figure 1.

Quantitative RT-PCR. For PCR analysis, 1 μ g RNA was reverse transcribed to cDNA using Superscript II reverse transcriptase and random hexamer primers (Invitrogen, Merelbeke, Belgium). The resulting RT-products were essentially amplified as previously described (Jiang *et al.*, 2003; Schwartz *et al.*, 2002). Three extra steps were included to ensure the purity of the PCR products: 95°C for 15 s, 60°C for 20 s, and 95°C for 15 s. The primers used for amplification and the products expected are described in (Jiang *et al.*, 2003; Schwartz *et al.*, 2002). The RNA levels were normalized using 18S and compared with the RNA levels in undifferentiated BMSC (negative control) and freshly isolated primary rat hepatocytes (positive control). As a negative control for the primers, a no template cDNA-PCR reaction was run under the same conditions. The authenticity and size of the PCR products were confirmed by melting curve analysis (using software provided by Perkin Elmer, Lennik, Belgium) and gel electrophoresis.

Immunocytochemistry. Differentiated BMSC were fixed either with ethanol for 10 min at –20°C (cytoskeletal proteins) or with 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA) for 10 min at 4°C, followed by incubation with 100mM glycine to saturate reactive groups (nuclear and cytoplasmic markers). The fixed cells were permeabilized for

A) Sequential exposure to liver-specific factors



B) Exposure to a cocktail of liver-specific factors




FIG. 1. Schematic presentation of the differentiation protocol. BMSC, at 100% confluency, were exposed either sequentially (A) or simultaneously (B) to liver-specific factors. D0*, day that BMSC were plated at 21×10^3 cells/cm² on collagen type I in low-serum expansion medium.

15 min with 0.1% Triton in phosphate-buffered saline (Electron Microscopy Sciences) and blocked for 30 min with 1% bovine serum albumin/5% donkey serum block buffer at room temperature. After blocking, cells were incubated overnight at 4°C with primary antibody (fluorochrome-conjugated or non-conjugated) and washed three times with phosphate-buffered saline. In case the primary antibody was not conjugated, cells were incubated for 2 h at room temperature with secondary fluorochrome-conjugated antibody. After incubation, slides were washed again with 0.1% Triton in phosphate-buffered saline and mounted with Vectashield with DAPI (Vector Laboratories, Burlingame, CA). As a negative control, cells were incubated with appropriate gamma immunoglobulines (Jackson Immunoresearch, Cambridgeshire, UK) and immunostained under the same conditions. In order to evaluate the localization of cytochrome P450 (CYP) proteins, mitochondria and endoplasmic reticulum were counterstained with the carbocyanine dye DiOC₆ (Molecular probes, Invitrogen). Cells were analyzed using fluorescence microscopy with a Zeiss Axiovert scope. To enumerate the number of cells expressing a given marker, all nuclei of positive-stained cells were counted and compared to the total number of cells evaluated. The primary antibodies against alpha-fetoprotein (AFP) (goat), hepatocyte nuclear factor (HNF)3 β (goat), and HNF1 α (rabbit) were purchased from Santa Cruz, (Heidelberg, Germany). Anti-cytokeratin (CK)18 (mouse, FITC-conjugated) and anti-albumin (ALB) (goat, FITC-conjugated) antibodies were from Sigma and Bethyl Laboratories (Montgomery, TX), respectively. The antibodies against CYP1A1 and CYP2B1/2 (both goat) came from Daiichi pure chemicals, BD Biosciences (Tokyo, Japan). Respective secondary antibodies were purchased from Jackson Immunoresearch.

Albumin ELISA. ALB concentrations, secreted into the culture media, were analyzed by ELISA (Koebe *et al.*, 1994).

Urea assay. The produced urea concentrations were, after 24-h exposure of the cells to 6mM NH₄Cl, colorimetrically measured in culture media according to the manufacturer's instructions (Quantichrom Urea assay kit, Bioassay Systems, Brussels, Belgium). Fresh culture media supplemented with 6mM NH₄Cl and 4 h-cultured adult rat hepatocytes were used as a negative and positive control, respectively.

Glycogen storage. Intracellular glycogen was analyzed by Periodic-acid-Schiff staining (PAS-kit 395B-1KT, Sigma) according to the manufacturer's

instructions. Amyloglucosidase (Sigma)-treated cells and 4 h-cultured adult rat hepatocytes were used as a negative and positive control, respectively.

Alkoxyresorufin-O-dealkylase assay. Ethoxyresorufin-O-deethylase (EROD) and pentoxyresorufin-O-dealkylase (PROD) activities were assessed as previously described (Donato *et al.*, 1993) with some minor modifications: in our setup, cells were incubated with 20 μ M 7-ethoxyresorufin and 18 μ M 7-pentoxyresorufin (all from Sigma) for 30 min.

To evaluate the inducibility of CYP2B1/2 and CYP1A1/2, respectively, cells were, after 24 days of differentiation, exposed to phenobarbital (PB; final concentration 1mM) and 3-methylcholantrene (MC; final concentration 2 μ M; all from Sigma). Media, supplemented with either PB or MC, were daily renewed from that time on. Fresh culture media and 4 h-cultured adult rat hepatocytes were used as a negative and positive control, respectively.

Statistics. Results are expressed as mean \pm SD. Statistical analyses were performed using one-way ANOVA and Student's *t*-test. The significance level was set at 0.05.

RESULTS

Characterization of the Differentiation Pattern of Rat BMSC into Hepatocyte-like Cells: Sequential versus Cocktail Exposure

Morphological Features

Previously, it has been shown that BMSC could differentiate into hepatocyte-like cells upon simultaneous exposure to a mixture of well-defined cytokines and growth factors (Schwartz *et al.*, 2002). However, using this approach, a rather heterogeneous population of epithelioid cells and other cell types was obtained. Moreover, no polygonal-shaped cells and only few binucleated cells were formed (Fig. 2). In an attempt




FIG. 2. Light-microscopic analysis of BMSC-derived hepatocyte-like cells upon sequential or simultaneous exposure to liver-specific factors at days 6 and 18. Original magnification of 20 \times 10, phase contrast.

to improve the differentiation of nonhaematopoietic stem cells from bone marrow into hepatocyte-like cells, BMSC were exposed to the same well-defined hepatogenic factors, but in a sequential way. More specifically, cytokines and growth factors were added at defined points in time, in a manner that closely resembles the *in vivo* process of embryonic liver development as specified in "Materials and Methods" section (Duncan, 2000; Jung *et al.*, 1999; Kinoshita and Miyajima, 2002; Schmidt *et al.*, 1995; Zaret, 2002). In this novel setup, epithelioid cells appeared in culture from day 6 on (Fig. 2). However, at that moment these cells were still surrounded by spindle-shaped cells. After 14 days, less fibroblastic cells were seen and some binucleated cells appeared. After 18 days, most cells exhibited a polygonal shape (Fig. 2).

Characterization at the Molecular Level

In a next set of experiments, we evaluated whether these morphological differences were associated with distinct patterns of differentiation at the molecular level. Therefore, the expressions of early (AFP and HNF3 β) and late (ALB, CK18, and HNF1 α) liver-specific markers were analyzed at both the mRNA (Fig. 3) and protein levels (Figs. 4 and 5).

mRNA expression. In both sequential and cocktail culture conditions, AFP, HNF3 β , ALB, CK18, and HNF1 α were

expressed in a time-dependent manner during BMSC differentiation. Both the pattern and the level of expression, however, differed considerably between the culture methods. In fact, upon sequential exposure to liver-specific factors, maximal AFP mRNA expression occurred after 6 days (Fig. 3), 4 days later than seen in the cocktail condition, but was 1.2-fold higher than the maximal level observed in cocktail-exposed cells. AFP mRNA expression disappeared completely in both conditions by day 11 of culture. In sequentially treated cells, down-regulation of AFP mRNA expression was nicely followed by a second transient, though more pronounced, induction of the early liver-specific marker HNF3 β as well as by a steady upregulation of the late hepatic markers ALB, CK18, and HNF1 α (Fig. 3). More specifically, HNF3 β mRNA expression started at day 2, reached maximal levels at day 10 and decreased rapidly thereafter (Fig. 3). ALB and CK18 mRNA expression, on the other hand, gradually increased from days 4 and 10 of culture, respectively, until maximal levels were reached at day 18 (Fig. 3). In sharp contrast to these observations, changes in HNF3 β , ALB, and CK18 mRNA levels were negligible upon simultaneous exposure to all hepatogenic factors ($p < 0.001$; one-way ANOVA). In addition, the mRNA of the late liver-specific marker ALB remained very low in cocktail-exposed BMSC, suggesting an immature hepatic differentiation status. Finally, upon sequential exposure, HNF1 α




FIG. 3. Analysis of hepatocyte differentiation at the mRNA level (abundance in cultured cells relative to freshly isolated rat hepatocytes [%]). BMSC were either sequentially or simultaneously exposed to liver-specific factors. Values represent means of three independent experiments. The dotted lines represent nontested time points. They are assumptions, based on the existing expression pattern.




FIG. 4. Characterization at the protein level of BMSC differentiation into hepatocyte-like cells upon sequential exposure to liver-specific factors. Immunocytochemistry was performed for AFP-cy3, HNF3 β -cy3, CK18-FITC, HNF1 α -cy3, and ALB-FITC. Nuclear counterstaining was assessed using DAPI. Original magnification of $\times 320$. Scale bar, 50 μ m. Stainings shown have the same magnification and are representative for at least five separate experiments.

mRNA expression gradually increased from day 6 on whereas in the cocktail condition, HNF1 α mRNA induction was delayed by 4 days and occurred only transiently (Fig. 3). Moreover, maximal levels, obtained at day 12, were about twofold lower than the levels observed in 12-day-old BMSC in the sequential condition. Thus, sequentially exposed BMSC underwent a consecutive array of developmental stages comparable with *in vivo* hepatogenesis while exposure to a cocktail of cytokines and growth factors induced an aberrant expression pattern of differentiation when compared to liver embryogenesis.

Protein expression. In order to support the results obtained at the mRNA level, immunocytochemistry analyses were performed in parallel (Figs. 4 and 5). After 4 days of differentiation, cells expressed AFP, regardless of the experimental setup (Figs. 4 and 5). Concomitantly to the results found at the mRNA level (Fig. 3), AFP expression occurred only transiently in both conditions (Figs. 4 and 5) and was undetectable by day 12 of culture (data not shown). Upon sequential exposure to liver-specific factors, a maximal positive staining of HNF3 β ($92 \pm 8\%$) was noticed at day 10, leveling off thereafter (Fig. 4). Treatment with all factors




FIG. 5. Characterization at the protein level of BMSC differentiation into hepatocyte-like cells upon simultaneous exposure to liver-specific factors. Immunocytochemistry was performed for AFP-cy3, HNF3 β -cy3, CK18-FITC, HNF1 α -cy3, and ALB-FITC. Nuclear counterstaining was assessed using DAPI. Original magnification of $\times 320$. Scale bar, 50 μ m. Stainings shown have the same magnification and are representative for at least five separate experiments.

simultaneously, however, revealed no more than $24 \pm 7\%$ HNF3 β -positive cells throughout the culture period (Fig. 5). As differentiation progressed, extensively increased stainings for ALB, CK18, and HNF1 α were detected upon sequential exposure to cytokines and growth factors, in accordance with the results obtained at the RNA level (Figs. 3 and 4). Consequently, after 18 days, $92 \pm 2\%$, $94 \pm 3\%$, and $89 \pm 9\%$ of the cells, respectively, stained positive for these markers (Fig. 4), which is in sharp contrast to only $32 \pm 4\%$, $63 \pm 5\%$, and $22 \pm 4\%$ of the cocktail-exposed cells, respectively ($p < 0.001$; Student's t -test) (Fig. 4).

In addition, in order to state the immunocytochemistry data with certainty, immunoblotting has been performed in parallel once (data not shown). In line with the previous results obtained at both the mRNA and protein level, sequentially exposed cells expressed liver-specific proteins more abundantly than cells in the cocktail setup. However, since this approach consumes large numbers of cells, i.e., at least 25–50 μ g of protein is needed to analyze one liver-specific marker at one point in time, the analysis was not repeated. Alternatively, as measuring CYP activity (the set of EROD/PROD) and their inducibility are widely accepted as final end point to evaluate the suitability of




FIG. 6. ALB secretion in sequentially- and cocktail-exposed BMSC. The results shown are representative for five independent experiments, each performed in duplicate. *, ***: ALB-secretion significantly differs among sequentially- and cocktail-exposed BMSC with $p < 0.05$ and $p < 0.001$, respectively (Student's *t*-test). \$\$: ALB-secretion in sequentially exposed BMSC is significantly upregulated from day 15 on with $p < 0.01$ (Student's *t*-test).

cells as *in vitro* models for pharmaco-toxicological screening of drugs (De Smet *et al.*, 2001; Donato *et al.*, 1993, 2003; LeCluyse *et al.*, 1996; Rogiers and Vercruysse, 1993), we enlarged, in a next set of experiments, the data set on cell functionality in order to increase confidence in our data.

Hepatic Functionality

In order to assess whether these hepatocyte-like cells derived from the bone marrow also acquired typical functional hepatic features, ALB secretion, ammonia metabolism, glycogen storage, expression of CYP proteins in parallel with their activity and inducibility were evaluated.

ALB secretion. Sequentially treated BMSC significantly upregulated the ALB secretion rate from day 15 onward ($p < 0.01$, Student's *t*-test) (Fig. 6). On the contrary, BMSC exposed to a cocktail of liver-specific factors did not secrete ALB above basal levels, corresponding to $0.55 \mu\text{g/ml}$ (Fig. 6).

Ureogenesis. Upon sequential exposure to hepatogenic factors, the urea production increased over culture time, reaching adult levels after 30–33 days. In contrast, cocktail-exposed cells synthesized, even at peak production, 24% significant lower urea levels ($p < 0.05$; Student's *t*-test) (Fig. 7).

Glycogen storage. Furthermore, upon sequential treatment with cytokines and growth factors, glycogen uptake was first seen after 21 days of culture, 6 days earlier than in the cocktail condition. After 30 days of culture, about 86% of the cells stored glycogen, regardless of the culture method (Fig. 8).

CYP protein-expression, activity, and inducibility. In the sequential setup, phase I CYP1A1 and CYP2B1/2 proteins were expressed within and nearby the endoplasmic reticulum and mitochondria (Fig. 9). The level of expression gradually




FIG. 7. Urea production in sequentially- and cocktail-exposed BMSC. Gray area represents urea levels, produced by 4 h-cultured adult rat hepatocytes. The graph is representative for four separate experiments, each performed in duplicate. *, **: Urea production significantly differs among sequentially- and cocktail-exposed BMSC with $p < 0.05$ and $p < 0.01$, respectively (Student's *t*-test).

increased as differentiation progressed. After 30 days, 78 ± 1 and $79 \pm 3\%$ of the cells stained positive for CYP1A1 and CYP2B1/2, respectively (Fig. 10). In sharp contrast to these observations, cocktail-exposed cells only showed modest CYP expression over culture time (Figs. 9 and 10).

In addition, we investigated whether CYP1A1 and 2B1/2 were functionally active by measuring the respective EROD and PROD activities in both conditions (Figs. 11 and 12).

In line with the results found at the protein level, sequentially exposed cells exhibited markedly higher EROD and PROD activity rates compared to the cocktail model ($p < 0.05$ at days 36 and 39; Student's *t*-test) (Figs. 11 and 12). Upon sequential exposure to liver-specific factors, a transient fourfold increase in PROD activity was displayed by days 27–30, approaching the level of 4 h-cultured adult rat hepatocytes, versus only a twofold increase after cocktail treatment (Fig. 11). In addition, in the former setup, EROD activity gradually increased from days 27 to 36 towards levels measured in 4 h-cultured adult rat hepatocytes, whereas CYP1A1/2-dependent activities appeared only transiently in cocktail-exposed cells between days 30 and 33 and declined to almost nondetectable levels on day 36 (Fig. 12).

CYP-inducibility is considered as the most representative metabolic function of the adult hepatic phenotype (Gomez-Lechon *et al.*, 2004; Rogiers and Vercruysse, 1993). Therefore, the responsiveness of both CYP1A1/2 and CYP2B1/2 to their respective prototype inducers MC and PB was analyzed in parallel. PROD activities were induced up to 1.4-fold after 6-day exposure to PB (i.e., on day 30), regardless of the experimental setup (Fig. 11). The inducibility persisted for 6 days in sequentially exposed cells but not in the cocktail condition. A significant CYP1A1/2-dependent response to MC was observed on days 36–39 ($p < 0.001$ and $p < 0.01$ at days 36 and 39, respectively; Student's *t*-test) in the sequential model. Conversely, MC barely induced EROD activities upon culture with all liver-specific factors simultaneously (Fig. 12).




FIG. 8. Glycogen storage in 30-day-old sequentially- (A) and cocktail-exposed BMSC (B) and 4 h-cultured adult rat hepatocytes (C), in the presence (1) and absence (2) of amyloglucosidase, respectively. Glycogen and nuclei are colored magenta and blue, respectively. Original magnification of $\times 400$. Stainings shown are representative for three separate experiments.

DISCUSSION

In recent years, adult-derived stem cells have become a hot topic in the field of molecular, cellular, and clinical biology, as well as in pharmaco-toxicology. Indeed, stem cells have an extensive self-renewing potential and many of them are considered multipotent (Jackson *et al.*, 2001; Krause *et al.*,

2001; Theise *et al.*, 2000; Vourc'h *et al.*, 2004). This interest in adult stem cells has in particular been triggered by the numerous ethical dilemmas surrounding the use of embryonic stem cells in preclinical and clinical research (Henningson *et al.*, 2003; McLaren, 2001). The best-characterized stem cell compartment is the bone marrow consisting of two stem cell populations, referred to as the hematopoietic and the mesenchymal




FIG. 9. Detailed view of expression of phase I biotransformation enzymes at days 24 and 30 upon sequential or simultaneous exposure to liver-specific factors. Immunocytochemistry was performed for CYP1A1-cy3 and CYP2B1/2-cy3. Mitochondria and endoplasmic reticulum were counterstained with a green fluorescent carbocyanine. Nuclei were counterstained with DAPI. Original magnification of $\times 320$. Scale bar, 50 μm . Stainings shown have the same magnification and are representative for three separate experiments.




FIG. 10. Overall view of expression of phase I biotransformation enzymes at days 24 and 30 upon sequential or simultaneous exposure to liver-specific factors. Immunocytochemistry was performed for CYP1A1-cy3 and CYP2B1/2-cy3. Mitochondria and endoplasmic reticulum were counterstained with a green fluorescent carbocyanine. Nuclei were counterstained with DAPI. Magnification of $\times 112$. Scale bar, 50 μ m. Stainings shown have the same magnification and are representative for three separate experiments.

stem cells (Huttmann *et al.*, 2003). Previously, Schwartz *et al.* (2002) described a population of cells in postnatal rat bone marrow, copurified with mesenchymal stem cells, that were capable of differentiating into cells of endodermal (hepatocytes) origin upon exposure to well-defined hepatogenic factors. These culture conditions yielded, however, a mixture of epithelioid

cells and other cell types. Therefore, attempts were made here to improve the hepatic differentiation process through exposure of BMSC to the same liver-specific factors in a sequential time-dependent manner, reflecting their secretion during *in vivo* hepatogenesis (Duncan, 2000; Jung *et al.*, 1999; Kinoshita and Miyajima, 2002; Schmidt *et al.*, 1995; Zaret, 2002).




FIG. 11. PROD activities and responsiveness to 1mM PB in differentiated BMSC upon sequential or simultaneous exposure to liver-specific factors. PB was added daily, starting on day 24. Gray area represents PROD activity measured in untreated 4 h-cultured adult rat hepatocytes. The graph is representative for five separate experiments, each, performed in duplicate. *: PROD activity significantly differs among sequentially- and cocktail-exposed BMSC with $p < 0.05$ (Student's *t*-test). \$, \$\$: PB significantly induced PROD activity of sequentially-exposed BMSC with $p < 0.05$ and $p < 0.01$, respectively (Student's *t*-test).




FIG. 12. EROD activities and responsiveness to 2 μ M MC in differentiated BMSC upon sequential or simultaneous exposure to liver-specific factors. MC was added daily, starting on day 24. Gray area represents EROD activity measured in untreated 4 h-cultured adult rat hepatocytes. The graph is representative for five separate experiments, each performed in duplicate. *: EROD activity significantly differs among sequentially- and cocktail-exposed BMSC with $p < 0.05$ (Student's *t*-test). \$, \$\$\$: MC significantly induced EROD activity of sequentially exposed BMSC with $p < 0.01$ and $p < 0.001$, respectively (Student's *t*-test).

Under these culture conditions, BMSC acquired morphological features (polygonal-shaped and binucleated cells) similar to those of primary hepatocytes (Ferrini *et al.*, 1997; Katsura *et al.*, 2002). Furthermore, more than 85% of these epithelioid cells expressed liver-associated genes and proteins (AFP, HNF3 β , ALB, CK18, and HNF1 α) in a comparable time-dependent manner as observed during *in vivo* liver embryogenesis. Indeed, AFP expression is first detected in embryonic endoderm around E8.5 (Cascio and Zaret, 1991) and precedes ALB and HNF1 α expression, detected around E9.5 and E10.5, respectively (Ott *et al.*, 1991; Shiojiri, 1981). This finding implicates that, in this setup, the BMSC differentiation process could serve as a model of early mammalian endoderm differentiation. In contrast, upon exposure to a cytokine/growth factors-cocktail, the expression patterns differed from the normal sequence seen during *in vivo* hepatogenesis as HNF1 α expression preceded that of ALB. Indeed, HNF1 α is only expressed in fully differentiated cells and not in un- or dedifferentiated cells (Cereghini *et al.*, 1988), as was noticed here upon cocktail treatment. In addition, significantly lower levels of liver-specific markers were expressed. The higher levels of ALB and CK18 expression in the sequential condition are probably due to the higher levels of both the early (HNF3 β) and late (HNF1 α) transcription factors. It is well documented that liver-enriched transcription factors act cooperatively and synergistically to promote liver-specific gene transcription (Cereghini *et al.*, 1992; Darlington, 1999; Duncan, 2000; Hayashi *et al.*, 1999; Shim *et al.*, 1988). In this regard, it was previously shown that HNF3 β positively regulates the expression of HNF4 α and HNF1 α (Darlington, 1999; Duncan *et al.*, 1998). Furthermore, it is believed that HNF3 β serves as the initiator of a cascade of regulatory events resulting in endoderm induction (Ang *et al.*, 1993; Darlington, 1999; Duncan, 2000; Levinson-Dushnik and Benvenisty, 1997). Hence, the minor changes in HNF3 β expression levels in the cocktail condition may only result in low levels of ALB and CK18 transcripts and protein.

The initiation and induction of AFP expression is not yet completely understood. It can be assumed that additional factors are involved in its transcriptional activation, as in both culture conditions, only minimal levels of HNF3 β were detected at the time of AFP expression. Further research will be needed to fully elucidate the transcriptional hierarchy mediating differentiation of BMSC toward hepatocytes.

The presence of both morphologic and phenotypic features, similar to that of primary hepatocytes, does, however, not fully prove the differentiation of BMSC into mature hepatocytes. Indeed, during the terminal step of liver organogenesis, the liver becomes a functional and metabolic organ, performing an essential role as detoxifying center of the body (Gomez-Lechon *et al.*, 2004; Kinoshita and Miyajima, 2002; Zaret, 2002). Interestingly, functional maturation occurred in both experimental setups, but to a different extent. Hepatic metabolic functions, including ALB secretion, urea production,

storage of glycogen, and CYP-activity/inducibility, were manifested most prominently upon sequential exposure to hepatogenic factors. Under these culture conditions, ALB secretion was in fact significantly upregulated to levels comparable to those obtained in both 2- to 7-day-old immobilization and 7-day-old monolayer cultures of primary rat hepatocytes. The latter measurements are performed on a regular basis in our laboratory (Beken *et al.*, 2001; Vanhaecke *et al.*, 2004). In addition, both the urea production and EROD/PROD activities reached levels comparable to 4 h-cultured primary rat hepatocytes. Response to prototype inducers was as expected: pronounced upon exposure to MC and discrete upon PB treatment. The level of induction, however, remained lower in comparison to cultured adult rat hepatocytes. More specifically, EROD activity increased up to fourfold after 15-day exposure to MC in sequentially exposed BMSC versus maximal sevenfold in 2-day treated rat hepatocytes (Donato *et al.*, 1993). Nevertheless, to our best knowledge, this is the first time that EROD (CYP1A1/2) activity/inducibility is demonstrated in hepatocyte-like cells derived from BMSC.

The less mature phenotype of cocktail-exposed cells could possibly be ascribed to altered and lower expression of HNF-type liver-enriched transcription factors in this setup. Experiments using hepatoma cell lines and HNF-null mice have in fact demonstrated the important role of HNFs in the regulation of genes that are involved in biotransformation (*Cyps*) and ammonia metabolism (ornithine-transcarbamylase gene) (Gomez-Lechon *et al.*, 2004; Inoue *et al.*, 2002; Rodriguez-Antona *et al.*, 2002). Similar to the results reported here, inducible CYP2B1/2-activity was also found by Schwartz *et al.* (2002) after exposure to a cocktail of the same cytokines and growth factors, although at an earlier time in culture. Some variation in time-specific gene and protein expression could probably be attributed to intraspecies differences and subtle changes in the differentiation procedure (i.e., type of culture plate coating, serum, etc.).

In summary, during the first 18 days of the hepatic differentiation process of BMSC, cells, and sequentially exposed BMSC in specific, underwent a sequential array of developmental stages, characterized by the down- and upregulation of early and late liver-specific markers, respectively. As differentiation progressed, i.e., from day 18 onward, expression of mature hepatic markers persisted at steady levels (data not shown) and cells gradually underwent functional hepatic maturation. In specific, sequentially treated BMSC accomplished hepatic functions at levels comparable to those of primary rat hepatocytes, cultured for 4 h to 2 days. Our results thus clearly show that a more pronounced and homogeneous differentiation of BMSC into functional hepatocyte-like cells can be obtained by sequentially directing the differentiation process analogous to liver embryogenesis. Moreover, differentiation appears to occur via steps commonly defined for *in vivo* endodermal lineage specification and subsequent hepatocyte differentiation and maturation. Further investigations, in order

to elucidate the molecular mechanisms underlying the changes described herein, are underway.

This model opens new perspectives: it may not only be applicable to study endoderm differentiation *in vitro* but it also offers the possibility to purify and culture multipotent stem cells from nonembryonic origin as an unlimited cell source for pharmaco-toxicological research and testing, and cell and organ development. It might even open a road to trigger cell fate and "trans"-differentiate uncommitted cells from different tissues towards endodermal lineages.

SUPPLEMENTARY DATA

Supplementary data are available online at <http://toxsci.oxfordjournals.org/>.

ACKNOWLEDGMENTS

The authors thank B. Dejaegher for the valuable statistical advice and L. Grooten, B. Degreef, E. Desmedt, S. Coppens, W. Sonck, Y. Heremans, and M. Blackstad for their dedicated technical assistance. Research was funded by a Ph.D. grant of the Institute for the Promotion of Innovation through Science and Technology in Flanders (Instituut voor de aanmoediging van Innovatie door wetenschap en technologie in Vlaanderen) and grants from the Research Council (Onderzoeksraad) of the Vrije Universiteit Brussel, Belgium, and Fund for Scientific Research Flanders (Fonds voor Wetenschappelijk Onderzoek in Vlaanderen), Belgium. The project is also a part of the EU FP6 project, Lintop.

REFERENCES

- Ang, S. L., Wierda, A., Wong, D., Stevens, K. A., Cascio, S., Rossant, J., and Zaret, K. S. (1993). The formation and maintenance of the definitive endoderm lineage in the mouse: Involvement of HNF3/forkhead proteins. *Development* **119**, 1301–1315.
- Beken, S., De Smet, K., De Preter, M., Roels, F., Vercruysee, A., and Rogiers, V. (2001). Effects of L-proline on phase I and phase II biotransformation capacities of rat and human hepatocytes in long-term collagen gel cultures. *Altern. Lab. Anim.* **29**, 35–53.
- Cascio, S., and Zaret, K. S. (1991). Hepatocyte differentiation initiates during endodermal-mesenchymal interactions prior to liver formation. *Development* **113**, 217–225.
- Cereghini, S., Blumenfeld, M., and Yaniv, M. (1988). A liver-specific factor essential for albumin transcription differs between differentiated and dedifferentiated rat hepatoma cells. *Genes Dev.* **2**, 957–974.
- Cereghini, S., Ott, M. O., Power, S., and Maury, M. (1992). Expression patterns of vHNF1 and HNF1 homeoproteins in early postimplantation embryos suggest distinct and sequential developmental roles. *Development* **116**, 783–797.
- Darlington, G. J. (1999). Molecular mechanisms of liver development and differentiation. *Curr. Opin. Cell Biol.* **11**, 678–682.
- De Smet, K., Cavin, C., Vercruysee, A., and Rogiers, V. (2001). Collagen type I gel cultures of adult rat hepatocytes as a screening induction model for cytochrome P450-dependent enzymes. *Altern. Lab. Anim.* **29**, 179–192.
- Donato, M. T., Gomez-Lechon, M. J., and Castell, J. V. (1993). A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. *Anal. Biochem.* **213**, 29–33.
- Donato, M. T., Klocke, R., Castell, J. V., Stenzel, K., Paul, D., and Gomez-Lechon, M. J. (2003). Constitutive and inducible expression of CYP enzymes in immortal hepatocytes derived from SV40 transgenic mice. *Xenobiotica* **33**, 459–473.
- Duncan, S. A. (2000). Transcriptional regulation of liver development. *Dev. Dyn.* **219**, 131–142.
- Duncan, S. A., Navas, M. A., Dufort, D., Rossant, J., and Stoffel, M. (1998). Regulation of a transcription factor network required for differentiation and metabolism. *Science* **281**, 692–695.
- Ferrini, J. B., Pichard, L., Domergue, J., and Maurel, P. (1997). Long-term primary cultures of adult human hepatocytes. *Chem. Biol. Interact.* **107**, 31–45.
- Gomez-Lechon, M. J., Donato, M. T., Castell, J. V., and Jover, R. (2004). Human hepatocytes in primary culture: The choice to investigate drug metabolism in man. *Curr. Drug. Metab.* **5**, 443–462.
- Hayashi, Y., Wang, W., Ninomiya, T., Nagano, H., Ohta, K., and Itoh, H. (1999). Liver enriched transcription factors and differentiation of hepatocellular carcinoma. *Mol. Pathol.* **52**, 19–24.
- Henningson, C. T., Stanislaus, M. A., and Gewirtz, A. M. (2003). Embryonic and adult stem cell therapy. *J. Allergy Clin. Immunol.* **111**, 745–753.
- Huttmann, A., Li, C. L., and Dührsen, U. (2003). Bone marrow-derived stem cells and plasticity. *Ann. Hematol.* **82**, 599–604.
- Inoue, Y., Hayhurst, G. P., Inoue, J., Mori, M., and Gonzalez, F. J. (2002). Defective ureagenesis in mice carrying a liver-specific disruption of hepatocyte nuclear factor 4alpha (HNF4alpha). HNF4alpha regulates ornithine transcarbamylase in vivo. *J. Biol. Chem.* **277**, 25257–25265.
- Jackson, K. A., Majka, S. M., Wang, H., Pocius, J., Hartley, C. J., Majesky, M. W., Entman, M. L., Michael, L. H., Hirschi, K. K., and Goodell, M. A. (2001). Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. *J. Clin. Invest.* **107**, 1395–1402.
- Jiang, Y., Henderson, D., Blackstad, M., Chen, A., Miller, R. F., and Verfaillie, C. M. (2003). Neuroectodermal differentiation from mouse multipotent adult progenitor cells. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 11854–11860.
- Jiang, Y., Vaessen, B., Lenvik, T., Blackstad, M., Reyes, M., and Verfaillie, C. M. (2002). Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. *Exp. Hematol.* **30**, 896–904.
- Jung, J., Zheng, M., Goldfarb, M., and Zaret, K. S. (1999). Initiation of mammalian liver development from endoderm by fibroblast growth factors. *Science* **284**, 1998–2003.
- Katsura, N., Ikai, I., Mitaka, T., Shiotani, T., Yamanokuchi, S., Sugimoto, S., Kanazawa, A., Terajima, H., Mochizuki, Y., and Yamaoka, Y. (2002). Long-term culture of primary human hepatocytes with preservation of proliferative capacity and differentiated functions. *J. Surg. Res.* **106**, 115–123.
- Kinoshita, T., and Miyajima, A. (2002). Cytokine regulation of liver development. *Biochem. Biophys. Acta* **1592**, 303–312.
- Koebe, H. G., Wick, M., Cramer, U., Lange, V., and Schildberg, F. W. (1994). Collagen gel immobilisation provides a suitable cell matrix for long term human hepatocyte cultures in hybrid reactors. *Int. J. Artif. Organs* **17**, 95–106.
- Krause, D. S., Theise, N. D., and Collector, M. I. (2001). Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. *Cell* **105**, 369.
- LeCluyse, E. L., Bullock, P. L., Parkinson, A., and Hochman, J. H. (1996). Cultured rat hepatocytes. *Pharm. Biotechnol.* **8**, 121–159.
- Levinson-Dushnik, M., and Benvenisty, N. (1997). Involvement of hepatocyte nuclear factor 3 in endoderm differentiation of embryonic stem cells. *Mol. Cell. Biol.* **17**, 3817–3822.
- McLaren, A. (2001). Ethical and social considerations of stem cell research. *Nature* **414**, 129–131.
- Ott, M. O., Rey-Campos, J., Cereghini, S., and Yaniv, M. (1991). vHNF1 is expressed in epithelial cells of distinct embryonic origin during development and precedes HNF1 expression. *Mech. Dev.* **36**, 47–58.

- Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L., and Verfaillie, C. M. (2001). Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. *Blood* **98**, 2615–2625.
- Rodriguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, J. V., and Gomez-Lechon, M. J. (2002). Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: Molecular mechanisms that determine lower expression in cultured cells. *Xenobiotica* **32**, 505–520.
- Rogiers, V., and Vercruyse, A. (1993). Rat hepatocyte cultures and co-cultures in biotransformation studies of xenobiotics [review]. *Toxicology* **82**, 193–208.
- Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., and Birchmeier, C. (1995). Scatter factor/hepatocyte growth factor is essential for liver development. *Nature* **373**, 699–702.
- Schwartz, R. E., Reyes, M., Koodie, L., Jiang, Y., Blackstadt, M., Lund, T., Lenvik, T., Johnson, S., Hu, W. S., and Verfaillie, C. M. (2002). Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. *J. Clin. Invest.* **109**, 1291–1302.
- Shim, E. Y., Woodcock, C., and Zaret, K. S. (1988). Nucleosome positioning by the winged helix transcription factor HNF3. *Genes Dev.* **12**, 5–10.
- Shiojiri, N. (1981). Enzyme- and immunocytochemical analyses of the differentiation of liver cells in the prenatal mouse. *J. Embryol. Exp. Morphol.* **62**, 139–152.
- Theise, N. D., Nimmakayalu, M., Gardner, R., Illei, P. B., Morgan, G., Teperman, L., Henegariu, O., and Krause, D. S. (2000). Liver from bone marrow in humans. *Hepatology* **32**, 11–16.
- Vanhaecke, T., Henkens, T., Kass, G. E., and Rogiers, V. (2004). Effect of the histone deacetylase inhibitor trichostatin A on spontaneous apoptosis in various types of adult rat hepatocyte cultures. *Biochem. Pharmacol.* **68**, 753–760.
- Vourc'h, P., Romero-Ramos, M., Chivatakarn, O., Young, H. E., Lucas, P. A., El-Kalay, M., and Chesselet, M. F. (2004). Isolation and characterization of cells with neurogenic potential from adult skeletal muscle. *Biochem. Biophys. Res. Commun.* **317**, 893–901.
- Verfaillie, C. M. (2000). Stem cell plasticity. *Graft* **3**, 296–298.
- Wang, X., Willenbring, H., Akkari, Y., Torimaru, Y., Foster, M., Al-Dhalimy, M., Lagasse, E., Finegold, M., Olson, S., and Grompe, M. (2003). Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature* **422**, 897–901.
- Yoon, Y. S., Wecker, A., Heyd, L., Park, J. S., Tkebuchava, T., Kusano, K., Hanley, A., Scadova, H., Qin, G., Cha, D. H., et al. (2005). Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. *J. Clin. Invest.* **115**, 326–338.
- Zaret, K. S. (2002). Regulatory phases of early liver development: Paradigms of organogenesis. *Nat. Rev. Genet.* **3**, 499–512.